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ABSTRACT
More than 37 million people are living with HIV worldwide. Despite the
widespread use of antiretroviral therapy (ART), up to 70% of HIV-positive
individuals suffer from cognitive and behavioral deficits collectively known as
HIV-associated neurocognitive disorders (HAND). HIV-mediated damage to the
dopaminergic system is a mediating factor in HAND. Dopamine (DA) transporter
(DAT)-mediated reuptake is essential for maintaining DA homeostasis. Because
most ART cannot efficiently cross the blood-brain barrier (BBB), the brain serves
as a viral reservoir that facilitates the spread of infection to microglia and
astrocytes. Infected cells shed viral proteins such as Tat, which plays a critical
role in HIV infection-induced dysregulation of the dopaminergic system by its
allosteric inhibition of DAT. Because Tat does not compete with the DA uptake
site, blocking the Tat-DAT interaction will have minimal effects on normal
transporter function. In addition, cocaine, a DAT inhibitor, magnifies the effects of
Tat on neurotoxicity, which contributes to HAND severity in cocaine-abusing HIVinfected patients. We hypothesize that Tat protein inhibits dopamine (DA) uptake
by interacting with specific recognition binding residues on DAT thereby leading
to dopaminergic dysregulation observed in HAND. Targeting the Tat-DAT
interaction during the early stages of HIV-1 infection is therefore a potential
therapeutic strategy to prevent HAND.
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By

utilizing

integrated

computational

homology

modeling

and

pharmacological validation, key recognition binding residues on human DAT that
are critical to Tat-DAT interaction were identified. Mutations on these residues
attenuated Tat-induced inhibition of DAT uptake while preserving (Y88F, D203L)
or significantly enhancing (H547A) basal function of the transporter. H547A was
found to enhance DAT function through alterations in phosphorylation,
palmitoylation, and transporter conformation. Additionally, double (D206L/H547A)
and triple (Y88F/D206L/H547A) combinations of these mutations blocked Tat
inhibition. Introducing mutations on Tat1-86 (K19A, C22G) reversed the inhibitory
effects of the protein, indicative of disrupted Tat-DAT binding.
Finally, to probe the therapeutic feasibility of developing allosteric
modulators to block Tat and cocaine binding without interfering with normal DAT
function, the SRI compounds, novel quinazoline-based allosteric modulators,
were utilized. From the initial screening, SRI-32743 was selected due to its
effective

potency.

SRI-32743

pharmacologically

demonstrated

allosteric

properties and attenuated Tat inhibition in wild-type human DAT-expressing cells.
When administered systemically to inducible HIV-1 Tat transgenic mice after 14
days of Tat induction via doxycycline, SRI-32743 dose-dependently ameliorated
conditioned place preference for cocaine. These results demonstrate that
developing allosteric modulatory molecules which attenuate cocaine and Tat
binding to DAT will aid drug discovery efforts in the search for therapeutic
interventions for HIV-infected patients who are concurrent abusers of cocaine.
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CHAPTER 1
INTRODUCTION
1.1 SIGNIFICANCE
The introduction of antiretroviral therapy (ART) in the mid- to late nineties
has transformed human immunodeficiency virus type 1 infection (“HIV-1”, but will
also be referred to as “HIV” throughout this dissertation) from a fatal and terminal
diagnosis to a manageable chronic disease. Subsequently, the number of people
living with HIV has steadily risen throughout the decades. Currently, there are
about 37 million people living with HIV worldwide (Pustil 2016). This reflects the
dramatic reduction in mortality, increased access to ART, and improved life
expectancy (Simioni et al. 2010; Bonnet et al. 2013). Untreated HIV progressively
leads to the development of acquired immunodeficiency syndrome (AIDS), the
final stage of HIV infection (Vahlne 2009). Opportunistic infections that were once
a direct consequence of debilitating immunodeficiency have decreased overall
(Carroll and Brew 2017); however, the increased prevalence of disrupted
neurocognitive function has become one of the most common complications of
HIV (Sanmarti et al. 2014). These neurological complications are referred to as
HIV-associated neurocognitive disorders (HAND). Widespread access to ART
has relegated the most severe manifestations of HAND such as HIV encephalitis
and HIV-associated dementia (HAD) to rare occurrences (Heaton et al. 2010,
2011); however, the milder forms of HAND continue to persist, affecting up to
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70% of HIV-positive individuals (Sacktor et al. 2001; Cysique et al. 2004;
McArthur 2004; Robertson et al. 2007; Heaton et al. 2008, 2010; Wright et al.
2008; Woods et al. 2009; Simioni et al. 2010). The longer life expectancy in HIVpositive individuals has consequently increased the prevalence of HAND (Simioni
et al. 2010; Brew and Chan 2014). This has dramatically altered patient
demographics, as individuals over 50 years old now make up the largest
percentage of persons living with HIV (Centers for Disease Control and
Prevention 2017). Interestingly, it has been found that drugs of abuse such as
cocaine

and

methamphetamine

have

a

synergistic

effect

on

the

neurodegenerative effects found in HIV-infected patients regardless of ART
treatment (Starace et al. 1998; Langford et al. 2003; Chana et al. 2006; Nath
2010; Purohit et al. 2011; Meade et al. 2011a; Meyer et al. 2014). The healthcare
burden of HAND will continue to rise, as estimates from other countries have
suggested that the number of HIV-positive patients with HAND will increase from
5- to 10-fold by the year 2030 (Cysique et al. 2011). There is no cure for HAND,
and considering its progressive and neurodegenerative nature, an early
intervention strategy is critical.
1.2 HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND)
Neurocognitive dysfunction in HIV-positive patients has been observed as
early as the 1980s, where the only well-defined neurological complication of HIV
was HIV-associated dementia (HAD) (Sanmarti et al. 2014). Patients with HAD
were primarily severely immunocompromised and were observed to have highly
advanced cognitive impairment that was accompanied by motor and behavioral
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deficits (Sanmarti et al. 2014). The introduction of ART in the mid- to late 1990s
has dramatically reduced the incidence of HAD (McArthur et al. 2005); however,
the milder forms of HAND have become more common throughout the years
(Heaton et al. 2010, 2011; Saylor et al. 2016). Despite having adequately
suppressed plasma viral load (<50 copies/mL) through ART, neurocognitive
impairment is still observed in these patients, which suggests that factors other
than systemic viral replication are at play. In 2007, the Frascati Criteria was
introduced, which further revised the HAND classification system into a spectrum
of neurocognitive disorders that range from the very mild to the most severe
(Antinori et al. 2007, 2013). Asymptomatic Neurocognitive Impairment (ANI), the
mildest stage of HAND, affects about 33% of HIV-positive patients, and is
characterized by neuropsychological impairment in at least two cognitive
domains without affecting activities of daily living. Mild Neurocognitive Disorder
(MND), which is a level higher than ANI, affects 20-30% of HIV-positive patients,
and is defined as mild to moderate impairment in at least two cognitive areas with
a disruption in activities of daily living. Currently, HAD, the most severe albeit
rare form of HAND, affects about 2-8% of HIV-positive patients, and is marked by
cognitive impairment in at least two cognitive domains and accompanied by
significant impairment in activities of daily living. The differential diagnosis of
HAND emphasizes that there must be no evidence of cognitive impairment that
does not have HIV as the underlying cause (Antinori et al. 2013).
Entry of HIV into a cell requires binding to CD4 (cluster of differentiation 4)
and an HIV co-receptor such as CXCR4 (CXC-chemokine receptor 4) or CCR5
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(CC-chemokine receptor 5) (Albright et al. 2003; González-Scarano and MartínGarcía 2005; Mocchetti et al. 2012). HIV entry into lymphocytes is mediated by
CXCR4, while CCR5 controls viral entry into monocytes and macrophages and is
thought to play a greater role in the spread and initiation of HIV infection (Doms
and Trono 2000; González-Scarano and Martín-García 2005; Anderson and
Akkina 2007; Mocchetti et al. 2012). Unlike monocytes, macrophages, and
microglia, neurons do not express CD4 and are therefore not susceptible to HIV
infection (González-Scarano and Martín-García 2005). However, neuronal
damage that stems from HAND occurs as a consequence of central nervous
system (CNS) exposure to direct and indirect factors: viral proteins and
neurotoxicity from ART (direct); and subsequent “bystander” trauma to neurons
from inflammation, perturbation of calcium and glutamate homeostasis, as well
as oxidative stress (indirect) (González-Scarano and Martín-García 2005; King
et al. 2006; Letendre et al. 2010; Clifford and Ances 2013). HIV infection in the
brain occurs within the first few weeks of initial infection through the “Trojan
horse” mechanism (Peluso et al. 1985; Haase 1986): the virus rapidly crosses
the selectively permeable blood-brain barrier (BBB) by piggybacking on infected
monocytes and lymphocytes that migrate to the CNS (Clements et al. 2002;
Orandle et al. 2002; Kim et al. 2003; Roberts et al. 2004; Williams et al. 2014).
Upon reaching the brain, the infected monocytes mature into HIV-infected
perivascular macrophages that produce more virions and facilitate the spread of
the virus (Albright et al. 2003; González-Scarano and Martín-García 2005).
Because most ART cannot cross the BBB, the brain serves as a viral reservoir as
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the virus spreads to other key cell types in the CNS susceptible to HIV infection
such as microglia and astrocytes (McArthur et al. 2010). As the infected cells
shed neurotoxic viral particles, proteins, and cytokines, viral load is increased in
the CNS, thereby facilitating continued infection, neurotoxicity, and subsequent
neuronal injury that are central to the development of HAND (Tornatore et al.
1991; Brown et al. 2006; Thompson et al. 2011; Desplats et al. 2013).
1.3 HIV TAT PROTEIN
Since HIV does not directly infect neurons (González-Scarano and MartínGarcía 2005) and cognitive impairment is still observed in patients with controlled
viral loads, neurodegeneration that results in HAND is only an indirect
consequence of viral replication. Viral proteins that are shed by HIV-infected cells
such as Tat (transactivator of transcription), gp120 (glycoprotein 120), and Vpr
(viral protein R) have been found to cause neurotoxicity and have been
implicated in HAND neuropathogenesis (Nath and Geiger 1998). Among the key
viral proteins, the regulatory protein Tat is one of the most studied (Gaskill et al.
2017; Zhu et al. 2018). Tat is a small nonstructural polypeptide composed of six
protein domains encoded by two exons. Amino acids 1-72 belong to the first five
domains and are encoded from the first exon, which is critical to the
transcriptional activity of Tat. These first five domains are the acidic domain
(amino acid residues 1-21), cysteine-rich domain (amino acid residues 22-37),
the hydrophobic core domain (38-48), a basic domain (48-57), and a glutaminerich domain (58-72). The sixth domain is a C-terminus domain of varying lengths,
usually comprised of amino acids 73-101 (but could include 58-101) and are
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encoded from the second exon (Bertrand et al. 2013). Majority of Tat found
isolated in HIV clinical samples is of the 101 amino acid variant (Tat 1-101), while
the shorter laboratory-adapted strain containing 86 amino acids (Tat1-86) is
widely used in research (Gaskill et al. 2017). However, reports have shown that
both Tat1-101 and Tat1-86 were found in clinical isolates from HIV-positive patients
(Barré-Sinoussi et al. 1983; Jeang et al. 1999). Furthermore, studies comparing
various forms of Tat have shown no marked differences between these types
(Ma and Nath 1997; Bertrand et al. 2013; Midde et al. 2013). The studies
reported in this dissertation have utilized Tat1-86.
Critical for viral replication, Tat is secreted by HIV-infected macrophages
and microglia, and due to its highly penetrative nature, it is readily absorbed by
uninfected cells (Frankel and Pabo 1988; Vivès et al. 1997; Frankel and Young
1998). These properties allow Tat to interact with a wide variety of cells and carry
out numerous functions. For instance, Tat has been found to activate dormant Tlymphocytes (Ott 1997), induce cellular apoptosis (Li et al. 1995; Westendorp et
al. 1995), modulate gene expression by disrupting intracellular signaling
cascades (Westendorp et al. 1995; Nath and Geiger 1998; Jeang et al. 1999),
attract monocytes (Albini et al. 1998), increase BBB permeability (Toborek et al.
2005), and even act as a growth factor for Kaposi-like cells (Trinh et al. 1999).
Post-mortem studies reveal the presence of Tat protein in the monocytes,
astrocytes, microglia, and dopamine (DA)-rich brain regions in samples from HIVinfected patients (Hofman et al. 1994; Bonwetsch et al. 1999; Del Valle et al.
2000). Tat has also been detected in the plasma, serum, and CSF of HIV-
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infected patients, with concentrations ranging from 1 ng/mL to 40 ng/mL
(Westendorp et al. 1995; Xiao et al. 2000). However, there is no clear consensus
in the literature regarding the actual concentration of biologically active Tat in
systemic circulation (Westendorp et al. 1995; Xiao et al. 2000); more studies and
detection methods must be developed. Nevertheless, Tat has been found to
possess neurotoxic properties (Sabatier et al. 1991; King et al. 2006). Though
the exact mechanism is unclear, some studies suggest that this may be due to
Tat-mediated excitotoxicity (Li et al. 2008), disruption of endogenous miRNA
patterns (Chang et al. 2011), and degradation of proteins associated with
microtubule and cytoskeletal formation in neurons (Aprea et al. 2006), all leading
to neuronal damage observed in HIV-infected patients. Exposure to Tat results in
perturbations to the dopaminergic system, which has been implicated in the
development of HAND (Purohit et al. 2011; Gaskill et al. 2017; Zhu et al. 2018).
The interplay of HIV infection and Tat protein in the perturbation of dopaminergic
neurotransmission in relation to HAND will be discussed in the next section.
1.4 HIV AND TAT ON DOPAMINERGIC NEUROTRANSMISSION
Dopamine (DA) is a neurotransmitter involved in the reward, cognition,
and motor control centers of the brain (Wise 2004). Dopaminergic homeostasis in
the brain is maintained by the dopamine transporter (DAT), which rapidly
sequesters extracellular DA back into the presynaptic neuron (Torres 2006;
Hamilton et al. 2014). Dysfunctional dopaminergic neurotransmission has been
implicated in the development of HAND (Purohit et al. 2011; Gaskill et al. 2017;
Zhu et al. 2018).
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Evidence from clinical samples and animal studies have shown that HIVmediated damage to dopaminergic neurons occur in the asymptomatic early
infection stage (Lopez et al. 1999; Koutsilieri et al. 2002b; Scheller et al. 2005).
HIV infection has been shown to affect the CNS metabolism of DA (Kumar et al.
2009, 2011; Horn et al. 2013; Meulendyke et al. 2014), as well cause disruption
in the brain’s dopaminergic system (Berger and Nath 1997; Kumar et al. 2009;
McIntosh et al. 2015). Significant neuronal damage to DA-rich areas in the brain
has been observed in HIV-infected patients who are undergoing ART (Kumar et
al. 2009, 2011; Scheller et al. 2010; Horn et al. 2013; Meulendyke et al. 2014) as
well as those who are not (Kieburtz et al. 1991; Berger et al. 1994; Sardar et al.
1996; Koutsilieri et al. 1997, 2002b, a; Di Rocco et al. 2000; Silvers et al. 2006).
In patients with HIV-associated dementia (HAD), neuroimaging studies have
revealed evidence of decreased levels of DAT in the basal ganglia,
demonstrating the key role DAT plays in the neuropathogenesis of HAND (Wang
et al. 2004). Furthermore, HIV-positive patients with a history of cocaine abuse
showed a further reduction in DAT density compared with HAD patients,
correlating with diminished performance in a battery of neurocognitive tests
(Chang et al. 2008). These studies clinically demonstrate the connection
between HIV infection, drugs of abuse, and the dopaminergic system.
Drugs of abuse, which alter dopamine levels in the brain, have been found
to accelerate HIV infection and HAND neuropathology (Dahal et al. 2015; Dash
et al. 2015). Cocaine, one of the most widely abused drugs in the HIV-positive
population, has been found to disrupt macrophage and lymphocyte function
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(Klein et al. 1993; Mao et al. 1996; Baldwin et al. 1997; Eisenstein and Hilburger
1998; Friedman et al. 2003), promote HIV infection in these target cells (Peterson
et al. 1990; Bagasra and Pomerantz 1993; Roth et al. 2002; Steele et al. 2003),
compromises BBB integrity (Dahal et al. 2015), and even accelerate disease
progression into AIDS (Dahal et al. 2015). Most importantly, as a very potent and
addictive CNS stimulator, cocaine, directly inhibits DA reuptake by blocking DAT,
leading to extracellular DA overflow. Consequently, elevated levels of dopamine
were found to promote HIV viral replication and infection of macrophages and
lymphocytes (Scheller et al. 2000; Gaskill et al. 2009), thereby accelerating
HAND neuropathogenesis. In the presence of HIV viral protein, Tat, which is also
an inhibitor of DAT, the effects of cocaine are magnified. Tat protein and cocaine
act synergistically to exacerbate HIV-related neurotoxicity, leading to HAND. This
creates a feedback loop wherein increased levels of dopamine due to DAT
inhibition interact with the dopamine receptors expressed on HIV-infected
macrophages (Gaskill et al. 2013, 2014), stimulating the release of more viral
proteins such as Tat (Rappaport et al. 1999), which not only accelerates viral
replication, but leads to neurotoxicity (Nath and Geiger 1998). Oxidative stress
characteristic of catecholamine breakdown due to the increased levels of
dopamine also contributes to damage observed in dopaminergic neurons in the
more advanced stages of HIV (Nath et al. 2000; Dahal et al. 2015). As the
disease further progresses, dopaminergic neurodegeneration occurs, leading to
more advanced clinical manifestations of HAND.
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1.5 THE HUMAN DOPAMINE TRANSPORTER (hDAT)
1.5.1 Structure and function
Dopaminergic dysregulation has been associated with the development of
HAND. At the center of HIV infection, viral protein release, and drugs of abuse
that contribute to HAND neuropathogenesis lies the dopamine transporter (DAT).
Human DAT, cloned in 1992, contains 620 amino acids and consists of 12
transmembrane (TM) domains with five intracellular and six extracellular loops
(Giros et al. 1992). DAT is a sodium-coupled symporter protein that is
responsible for maintaining dopamine (DA) homeostasis and terminating DA
neurotransmission through rapid sequestration of DA back into the neuron. DAT
carries extracellular DA against its concentration gradient back into presynaptic
neurons by deriving energy from coupling substrate translocation to existing Na+
and Cl- ionic gradients.

Intracellular DA that has been through the reuptake

process gets recycled for later use or is enzymatically broken down by
mitochondrial monoamine oxidases (MAO-A and MAO-B) as well as catechol Omethyltransferase (COMT) (McHugh and Buckley 2015; Sitte and Freissmuth
2015). Because dopamine reuptake is the most effective way to terminate
dopaminergic neurotransmission, any disruptions to DAT function and binding
would significantly affect the strength and duration of dopaminergic signaling in
the brain (Goodwin et al. 2009).
1.5.2 The neurotransmitter: sodium symporter family
DAT, also known as solute carrier protein SLC6A3, is a member of the
Neurotransmitter: Sodium Symporter (NSS) family, which includes other
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plasmalemmal transporters for monoamines such as the catecholamine
norepinephrine (NET; SLC6A2) and indolamine serotonin (SERT; SLC6A4), as
well as transporters for amino acids glycine and GABA (Chen and Reith 2000;
Sitte and Freissmuth 2015). DAT, NET, and SERT are also known as the
biogenic amine transporters (Wang et al. 2015). These transporters contain
intracellular amino and carboxyl termini that help control uptake and substrate
recognition via multiple putative post-translational modification sites (Foster et al.
2002; Fog et al. 2006; Wu et al. 2015; Moritz et al. 2015; Bermingham and
Blakely 2016) as well as variations in amino acid sequences that result in distinct
properties (Wang et al. 2015). These sequences, while highly conserved across
different species, vary greatly between the different types of transporters, which
suggests that transporter-specific regulation is influenced by these residues
(Eriksen et al. 2010).
1.5.3 Transporter regulation
DAT is regulated by complex and overlapping signaling systems that
require further exploration in order to fully harness its therapeutic potential. Three
of the most studied are through posttranslational modifications, ligand-transporter
interactions, and protein-protein interactions (Zhu and Reith 2008; Eriksen et al.
2010; Kristensen et al. 2011; Vaughan and Foster 2013).

Majority of these

regulatory mechanisms influence transporter trafficking and surface expression
on the plasma membrane (Eriksen et al. 2010). This is because the strength of
dopaminergic signaling is highly dependent on the number of available DAT on
the surface. For the purposes of this dissertation, I will focus on these three
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regulatory mechanisms and discuss how these relate to the development of
neurocognitive dysfunction that is characteristic of HAND.
1.5.4 Posttranslational modifications regulate DAT
Among signaling systems that regulate DAT, phosphorylation by protein
kinase C (PKC) is one of the most well characterized (Vaughan et al. 1997;
Foster et al. 2002, 2012; Guptaroy et al. 2009). Activation of PKC dampens DA
reuptake by increasing DAT endocytosis, which has been considered to be one
of the key players of transport downregulation (Ramamoorthy et al. 2011;
Vaughan and Foster 2013). The use of PKC activator PMA (phorbol 12-myristate
13-acetate) to promote DAT phosphorylation results in decreased DA uptake
Vmax due to the increased endocytic trafficking of active transporters into the
cytosol (Melikian 2004). In contrast, palmitoylation, a reversible lipid modification
that

regulates

proteins

in

a

similar

manner

to

that

of

phosphorylation/dephosphorylation, increases DA uptake (Linder and Deschenes
2007; Foster and Vaughan 2011). Through mutational and pharmacological
techniques, it has been found that the interplay between phosphorylation and
palmitoylation is a critical mechanism that governs DAT function (Moritz et al.
2015; Rastedt et al. 2016). This novel mechanism for DA uptake and control
sheds light on how DAT is regulated and offers a potential new mechanistic
target for the treatment of diseases involving dysfunctional dopaminergic
neurotransmission such as HAND.
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1.5.5 Ligand-transporter interactions influence DAT function
Drugs such as cocaine and the amphetamines target DAT and elevate
extracellular levels of DA, thereby interfering with dopaminergic reward pathways
and facilitating addiction (Zhu and Reith 2008). For instance, cocaine binds to the
central binding site of DAT and blocks the reuptake of DA by locking the
transporter in an outward-facing conformation, leading to significant potentiation
of dopaminergic neurotransmission in the brain (Giros and Caron 1993;
Mortensen and Amara 2003; Navratna et al. 2018). On the other hand,
amphetamines structurally resemble DA and therefore act as substrates of DAT
(Chen and Reith 2000). However, amphetamines competitively inhibit DA uptake
(Rothman and Baumann 2003; Han and Gu 2006) and promote the rapid efflux
of DA via reverse transport through DAT (Jones et al. 1998; Sitte et al. 2002;
Sitte and Freissmuth 2015; Hasenhuetl et al. 2018). The increased DA levels
due to drug use are magnified by HIV infection as well as the exposure to viral
proteins such as Tat. Tat protein directly interacts with DAT (Midde et al. 2013;
Yuan et al. 2015) and inhibits DAT-mediated DA reuptake through an allosteric
manner (Zhu et al. 2011). This mechanism will be discussed in the next section.
1.5.6 Protein-protein interactions
Protein-protein interactions are one of the major regulatory mechanisms
that govern DAT function (Eriksen et al. 2010; Kristensen et al. 2011). For
instance, it has been found that DA D2 receptors and G-protein βγ subunits
participate in direct protein-protein interactions with DAT (Lee et al. 2007; GarciaOlivares et al. 2013). Other proteins found to interact with DAT include
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syntaxin1A, ⍺-synuclein, parkin, and synaptogyrin-3, among many others
(Eriksen et al. 2010). In the context of HAND, the HIV envelope glycoprotein
gp120 has been found to impair DAT function in dopaminergic neurons by
decreasing DA uptake Vmax (Hu et al. 2009). Through surface plasmon
resonance (SPR) studies, glutathione-S-transferase (GST) pulldown assays, coimmunoprecipitation (Co-IP), and molecular dynamics modeling, it has been
previously found that Tat engages in a direct protein-protein interaction with DAT
(Midde et al. 2013; Yuan et al. 2015, 2016a). This interaction is through an
allosteric manner, where Tat protein does not directly compete for the DA binding
site (Zhu et al. 2009, 2011). Given the critical role Tat plays in DAT-mediated
dysfunction of dopaminergic neurotransmission in HAND patients, disrupting the
protein-protein interaction between Tat and DAT is therefore a potential approach
to prevent HIV-induced neurodegeneration. Identifying key residues that are
responsible for Tat-DAT interaction will provide potential targets for preventing
the development of HAND in HIV-positive patients, especially those who are
concurrent abusers of illicit drugs such as cocaine.
1.5.7

Computational

studies,

pharmacological

validation,

and

allosteric

modulation
Currently, the treatment of disorders of monoamine signaling target either
one of these four ways: 1) the binding of neurotransmitters to their respective
receptors, 2) the packaging of monoamine neurotransmitters into synaptic
vesicles by vesicular monoamine transporters (VMATs), 3) the enzymatic
degradation of neurotransmitters via the MAO and COMT enzymes, and 4) the
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reuptake of neurotransmitters back into presynaptic neurons by DAT, NET, and
SERT (Hasenhuetl et al. 2019). Because the Tat protein binds to DAT, the
studies presented in this dissertation utilize the last approach. Therefore,
characterizing the binding pocket of Tat and hDAT will aid in the development of
small molecular probes that would either block Tat binding to DAT or decrease
DAT’s affinity for Tat, effectively preventing HAND neuropathogenesis.
The DAT reuptake process follows the alternating access model wherein
the transporter cycles through an outward-facing to an inward-facing pose
(Hasenhuetl et al. 2019). Out of the 12 transmembrane (TM) domains of DAT,
TM1, TM6, and TM10 have been found to play a critical role in regulating the
conformational transition from outward-facing to inward-facing (Zhu et al. 2018).
Knowledge of the transporter’s conformation is important because certain drugs
and proteins bind favorably to DAT when it is at a specific conformational state.
Structural studies of monoamine transporters require x-ray crystal structures.
However, the field has struggled with solving the x-ray crystal structures of
mammalian NSS structures because obtaining sufficient amounts of stable
purified proteins has proven to be difficult (Navratna et al. 2018). While the x-ray
crystal structure of human DAT (hDAT) has yet to be solved, other homologous
transporters have been utilized to probe the structure and function of NSSs. For
instance, most homology studies conducted in the past several years on biogenic
amine transporters have utilized the x-ray crystal structure of bacterial orthologue
leucine transporter (LeuT) from Aquifex aeolicus as well as the Drosophila
melanogaster dopamine transporter (dDAT) (Piscitelli et al. 2010; Penmatsa et
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al. 2013, 2015; Penmatsa and Gouaux 2014; Wang et al. 2015). These
structures, along with advances in structural biology, computational modeling,
and medicinal chemistry, paved the way for the development of various
computational models of monoamine transporters, which includes the model of
the Tat-hDAT binding complex that is reported in this dissertation (Yuan et al.
2015, 2016a, 2018). This binding model, which is based on the dDAT x-ray
crystal structure, was determined using protein-protein docking techniques as
well as molecular dynamics (MD) simulations (Pierce et al. 2011; Case et al.
2012; Yuan et al. 2015).
Based on this Tat-DAT computational model, it has been found that Tat
favorably binds to the outward-facing state of hDAT at specific residues other
than the central DA binding site (Midde et al. 2013, 2015; Bucci 2015; Yuan et al.
2015, 2016a). Tat does not directly compete with the DA binding and therefore
inhibits DAT uptake by locking the transporter into an outward-facing
conformation. MD simulations using this Tat-hDAT model revealed several key
recognition binding residues on hDAT that are critical for binding to Tat:
Tyrosine88 (Y88), Lysine92 (K92), Tyrosine470 (Y470). Amino acid substitutions
on these residues resulted in the decrease (Y470A, Y470H, K92M) or
preservation (Y470F, Y88F) of DA uptake Vmax in cells expressing these hDAT
mutants (Midde et al. 2013, 2015). In cells expressing wild-type hDAT (WT
hDAT), the addition of recombinant HIV-1 Tat1-86 (rTat1-86) results in a 20-30%
decrease in DA uptake (Midde et al. 2013, 2015). However, Y88F, K92M, and
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Y470H attenuated Tat’s inhibitory effect on DA uptake, which validates the
predictions made in the Tat-hDAT computational model.
Tat-induced inhibition of DAT is mediated by binding of Tat to allosteric
binding site(s) on DAT, without directly interacting with the DA uptake site . This
provides a basis for a novel approach to address the problem by developing
compounds to attenuate Tat binding to DAT by an allosteric mechanism while
having minimal influence on physiological DA transport. A novel series of
quinazoline structure-based compounds (the SRI compounds) have been
developed, which function as allosteric modulators of monoamine transporters
and act as partial antagonists of DA uptake without the full inhibitory profile that is
typical of classic competitors of DAT (Pariser et al. 2008; Rothman et al. 2015). It
has been recently found that these SRI compounds attenuate the inhibitory
effects of Tat as well as cocaine on DA uptake and binding (Zhu et al. 2011; Sun
et al. 2017). Additionally, the computational model of the Tat-hDAT complex
reveals that SRI-30827 interferes with the interaction of Y470 and Y88 with the
EL6 region of hDAT, which most likely interferes with Tat binding on hDAT via an
allosteric mechanism (Sun et al. 2017). It is therefore of great clinical and
scientific interest to utilize pharmacological probes that could block Tat binding to
hDAT, especially in HIV-positive patients who are concurrent abusers of cocaine.
1.7 SIGNIFICANCE REVISITED
The overarching hypothesis of this dissertation is as follows: HIV-1 Tat
protein allosterically perturbs transporter function by interacting with specific
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recognition binding residues on DAT thereby leading to dopaminergic
dysregulation as seen in HAND. This dissertation is divided into several chapters:
Chapter 2 identifies additional recognition binding sites for Tat in DAT.
Through a combination of molecular dynamics predictions, site-directed
mutagenesis, and pharmacological validation, the predicted key binding sites and
the subsequent mutant DAT constructs were evaluated whether they (1a) alter
the functional and kinetic properties of DAT, (1b) are critical to Tat-DAT binding.
These mutant constructs were evaluated for the ability to preserve or improve
DAT function as well as to block Tat’s inhibitory effect on DAT.
Chapter 3 showcases mutational analysis studies on DAT constructs with
multiple mutations to elucidate the relationship between key recognition binding
residues. By using computational modeling predictions and experimental
validation via in vitro screening systems, multiple mutations in DAT were created
(as opposed to single residue substitutions) in order to (2a) determine the
pharmacological profiles of the mutant constructs, and (2b) identify the
conformational and structural alterations that occur when these multiple
mutations are combined. Mutants identified in Chapter 2 that preserve or improve
DAT function as well as attenuate Tat inhibition were identified as the best
candidates and were used to generate multiple mutations in the form of double
and triple mutant DAT constructs.
Chapter 4 evaluates whether novel allosteric ligands have the potential to
attenuate the inhibitory effects of Tat and cocaine. Novel quinazoline allosteric
ligands, which are partial antagonists for monoamine transporters, were
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pharmacologically characterized in vitro using cells expressing human DAT. This
chapter will (3a) identify their kinetic characteristics and potency as well as their
allosteric modulatory effects on DAT. Out of the series of ligands, the most potent
and ideal candidates were selected and then (3b) determined whether they can
attenuate the inhibitory effects of Tat on DAT in vitro. These were used to modify
structure-activity relationship data to guide the optimization of these ligands as
well as to identify one promising candidate. Finally, (3c) the candidate ligand’s
ability to improve behavioral phenotypes in the inducible Tat transgenic (iTat-tg)
mouse model was evaluated.
This project will provide novel insights regarding the regulation of the
dopamine transporter, which could aid in the field’s current search for more DAT
modulators to stabilize dopaminergic dysregulation as seen in HAND patients.
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CHAPTER 2

MOLECULAR MECHANISM: THE HUMAN DOPAMINE
TRANSPORTER HISTIDINE 547 REGULATES BASAL AND HIV-1
TAT PROTEIN-INHIBITED DOPAMINE TRANSPORT1

1

Quizon, P. M., Sun, W. L., Yuan, Y., Midde, N. M., Zhan, C. G., & Zhu, J. (2016). Molecular
mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat
protein-inhibited dopamine transport. Scientific reports, 6, 39048.
Reprinted here under a Creative Commons Attribution 4.0 International License (CC-BY).
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
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ABSTRACT: Abnormal dopaminergic transmission has been implicated as a risk
determinant of HIV-1-associated neurocognitive disorders. HIV-1 Tat protein
increases synaptic dopamine (DA) levels by directly inhibiting DA transporter
(DAT) activity, ultimately leading to dopaminergic neuron damage. Through
integrated computational modeling prediction and experimental validation, we
identified that histidine547 on human DAT (hDAT) is critical for regulation of
basal DA uptake and Tat-induced inhibition of DA transport. Compared to wild
type hDAT (WT hDAT), mutation of histidine547 (H547A) displayed a 197%
increase in DA uptake. Other substitutions of histidine547 showed that DA
uptake was not altered in H547R but decreased by 99% in H547P and 60% in
H547D, respectively. These mutants did not alter DAT surface expression or
surface DAT binding sites. H547 mutants attenuated Tat-induced inhibition of
DA transport observed in WT hDAT. H547A displays a differential sensitivity to
PMA- or BIM-induced activation or inhibition of DAT function relative to WT
hDAT, indicating a change in basal PKC activity in H547A. These findings
demonstrate that histidine547 on hDAT plays a crucial role in stabilizing basal DA
transport and Tat-DAT interaction. This study provides mechanistic insights into
identifying targets on DAT for Tat binding and improving DAT-mediated
dysfunction of DA transmission.
2.1 INTRODUCTION
An estimated thirty-four million people worldwide are living with HIV. More
than 50% of HIV-1 positive individuals suffer from neurological complications
collectively referred to as HIV-1-associated neurocognitive disorders (HAND)
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(Heaton et al. 2010). HAND is a spectrum of disorders generally divided into
three main groups: asymptomatic neurocognitive impairment (ANI; 33%), mild
neurocognitive disorders (MND, 20-30%), and the more severe albeit rare HIVassociated dementia (HAD; 2-8%) (McArthur et al. 2010; Heaton et al. 2010).
Majority of HAND patients experience deficits in memory, concentration, and
decision-making. HAND patients present neuropathological conditions that
emerge from the continued exposure of the central nervous system (CNS)
tissues to HIV-1, viral proteins, immune inflammation, and cART (King et al.
2006; Clifford and Ances 2013). Currently, there are no promising therapeutic
strategies for HAND. Considering the progressive and neurodegenerative nature
of HAND, establishing an early intervention strategy would be beneficial to the
preservation of neurocognitive function in HIV-infected individuals.
Converging lines of clinical observation, supported by imaging (Wang et
al. 2004; Chang et al. 2008), neuropsychological performance testing (Meade et
al. 2011b; Kumar et al. 2011), and postmortem examinations (Gelman et al.
2012), have implicated dopamine (DA) dysregulation with the abnormal
neurocognitive function observed in HAND (Berger and Arendt 2000; Purohit et
al. 2011). DA-rich brain regions (basal ganglia and related structures) are highly
susceptible to the effects of both HIV infection and substance use. In the early
stage of HIV infection, increased levels of DA and decreased DA turnover are
found in the cerebrospinal fluid of therapy-naïve HIV patients with asymptomatic
infection (Scheller et al. 2010), which may contribute to decreased levels of DA
in DA-rich brain regions (Sardar et al. 1996; Kumar et al. 2009, 2011) in the
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advanced stages of HIV infection. Importantly, HIV-induced elevated levels of
extracellular DA in the CNS can stimulate viral replication in human
macrophages within DA-rich brain regions (Gaskill et al. 2009, 2013, 2014),
resulting in viral protein release. It is commonly accepted that viral replication and
proteins within the CNS are correlated with the persistence of HIV-related
neuropathology and subsequent neurocognitive deficits (Frankel and Young
1998; Power et al. 1998; Brach-Werner 1999; Johnston et al. 2001). Among HIV1 viral proteins, transactivator of transcription (Tat) plays a crucial role in the
neurotoxicity and cognitive impairment evident in neuroAIDS (Rappaport et al.
1999; King et al. 2006). Tat can be detected in DA-rich brain areas (Del Valle et
al. 2000; Hudson et al. 2000; Lamers et al. 2010) and in the sera (Westendorp et
al. 1995; Xiao et al. 2000) of HIV-1 infected patients. Long-term viral exposure
can accelerate damage in the mesocorticolimbic DA system (Nath et al. 1987;
Berger and Arendt 2000; Koutsilieri et al. 2002b) and to the brain pathways
controlling motivation (Wise and Bozarth 1987; Everitt and Robbins 2005;
Berridge 2007). DA transporter (DAT)-mediated DA reuptake is critical for normal
DA homeostasis. Human DAT (hDAT) activity is strikingly reduced in HIV-1infected cocaine-using patients, correlating with the severity of HIV-1 associated
cognitive deficits (Wang et al. 2004; Chang et al. 2008). In vitro, the interplay of
Tat and cocaine augments synaptic DA levels and Tat release by inhibiting DA
transporter (DAT) activity (Zhu et al. 2009; Ferris et al. 2010). By producing
oxidative stress-induced damage to dopaminergic neurons, prolonged exposure
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to Tat protein eventually causes DAT-mediated dysregulation of DA to accelerate
the progression of HAND (Purohit et al. 2011).
Through integrated computational modeling prediction and experimental
validation, we have identified key residues in hDAT with which Tat interacts,
which are critical for Tat-induced inhibition of DAT and transporter conformational
transitions (Midde et al. 2013, 2015; Yuan et al. 2015). Our studies provide
mechanistic insights into identifying residues on DAT for Tat binding, which
allows the exploration of the molecular targets on DAT for therapeutic
interventions,

improving

neurocognitive

function

of

HAND.

Our

recent

computational modeling study demonstrated that mutation of histidine to alanine
at hDAT 547 (H547A) increases DA transport and attenuates Tat inhibitory effect
on DAT function (Yuan et al. 2016b). Basal DAT activity is regulated by several
protein kinases and phosphatases (Vaughan et al. 1997; Daniels and Amara
1999; Foster et al. 2002; Vuorenpää et al. 2016). Activation of protein kinase C
(PKC) induces downregulation of DA reuptake (Vaughan et al. 1997; Foster et al.
2002; Melikian 2004). In the present study, we pharmacologically determined the
potential contribution of PKC phosphorylation to H547A-induced enhancement of
DA transport by promoting or inhibiting of PKC activation. We also evaluated the
functional influence of other substitutions of Histidine547 (His547) and its
associated residues, tyrosine548 and tyrosine551, in DA transport as well as Tatinduced inhibition of DA uptake.
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2.2 MATERIALS AND METHODS
2.2.1 Predicting the site for hDAT binding with Tat
The binding structure of hDAT with HIV-1 clade B type Tat was modeled
and simulated based on the nuclear magnetic resonance (NMR) structures of Tat
(Péloponèse et al. 2000) and the constructed structure of hDAT-DA complex.
The protein-protein docking program ZDOCK (Pierce et al. 2011) was used to
determine the initial binding structure of the hDAT-Tat complex. A total of
220,000 potential conformations were generated based on 11 NMR structures of
Tat, then all of these conformations were evaluated and ranked by ZRANK
(Pierce and Weng 2007). Top-3,000 conformations selected from the proteinprotein docking process were submitted to energy minimizations, and the docked
structures were ranked according to the binding affinity estimated by using the
Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method
(Miller et al. 2012). Then the top-256 conformations were selected for further
evaluation by performing molecular dynamics (MD) simulations. Based on the
MD simulations, the most favorable hDAT-Tat binding mode (with the best
geometric matching quality and reasonable interaction between hDAT and Tat)
was identified, and the final hDAT-Tat binding structure was energy-minimized
for analysis.
2.2.2 Construction of plasmids
All point mutations of His547, Tyrosine548 (Tyr548), and Tyrosine551
(Tyr551) in hDAT were selected based on the predictions of the threedimensional computational modeling and simulations. Based on the favorable
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hDAT-Tat binding mode (Figure 2.1), it could be expected that mutations of
His547 would eliminate a hydrogen bond between D-H547 and T-R49, which
impair the binding affinity of Tat with hDAT, thereby diminishing Tat-induced
inhibition of DA uptake. Mutations in hDAT at His547 [Histidine to Alanine
(H547A), Proline (H547P), Arginine (H547R), or Aspartic acid (H547D)], Tyr548
(tyrosine to histidine, Y548H), and Tyr551 (tyrosine to histidine, Y551H) were
generated based on wild type hDAT (WT hDAT) sequence (NCBI, cDNA clone
MGC: 164608 IMAGE: 40146999) by site-directed mutagenesis. Synthetic cDNA
encoding hDAT subcloned into pcDNA3.1+ (provided by Dr. Haley E Melikian,
University of Massachusetts) was used as a template to generate mutants using
QuikChange™ site-directed mutagenesis Kit (Agilent Tech, Santa Clara CA). The
sequence of the mutant construct was confirmed by DNA sequencing at
University of South Carolina EnGenCore facility. Plasmid DNA were propagated
and purified using a plasmid isolation kit (Qiagen, Valencia, CA, USA).
2.2.3 Cell culture and DNA transfection
PC12 cells (ATCC® CRL-1721TM, American Type Culture Collection,
Manassas, VA) were maintained at 37 °C in a 5% CO2 incubator in Dulbecco’s
modified eagle medium (DMEM, Life Technologies, Carlsbad, CA) supplemented
with 15 % horse serum, 2.5 % bovine calf serum, 2 mM glutamine, and
antibiotics (100 U/ml penicillin and 100 µg/mL streptomycin). Twenty four hours
prior to transfection, cells were seeded into 24 well plates at a density of 1×10 5
cells/cm2, or allowed to reach 100% confluence on plates. Cells were transfected
with plasmids of WT hDAT or its mutants using Lipofectamine 2000 (Life
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Technologies, Carlsbad, CA). Twenty four hours after transfection, intact cells or
cell suspensions were used for experiments.
2.2.4 [3H]DA uptake assay
To determine whether DAT mutants alter DAT function, the maximal
velocity (Vmax) or Michaelis-Menten constant (Km) of [3H]DA uptake were
examined in PC12 cells transfected with WT hDAT or its mutants as previously
reported (Midde et al. 2013). Intact PC12 cells in 24-well plates were rinsed twice
in Krebs-Ringer-HEPES (KRH) buffer (final concentration in mM: 125 NaCl, 5
KCl, 1.5 MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 10 D-glucose, 25 HEPES, 0.1 EDTA,
0.1 pargyline, and 0.1 L-ascorbic acid; pH 7.4). The cells were then preincubated
for 10 min at room temperature in KRH buffer with or without nomifensine for
nonspecific binding (10 µM, final concentration). Next, the cells were incubated in
KRH containing one of six concentrations of unlabeled DA (final DA
concentrations, 0.03–5 µM) and a fixed concentration of [3H]DA (500,000
dpm/well, specific activity, 21.2 Ci/mmol; PerkinElmer Life and Analytical
Sciences, Boston, MA) at room temperature for 8 min. Nonspecific uptake of
each concentration of [3H]DA (in the presence of 10 µM nomifensine) was
subtracted from total uptake to calculate specific DAT-mediated uptake.
To determine whether H547A-induced increase in Vmax was mediated by a
phosphorylation-dependent mechanism, kinetic analysis of [3H]DA uptake was
measured in the presence or absence of PKC activator PMA (Tocris, Bristol, UK)
or PKC inhibitor BIM (Sigma-Aldrich, St. Louis, MO). The concentrations were
chosen based on previous reports (Melikian and Buckley 1999; Navaroli et al.
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2011). In brief, intact PC12 cells transfected with WT or H547A-hDAT were
preincubated with or without PMA or BIM (1 µM, final concentration) for 30 min at
37 °C or room temperature and then incubated with six concentrations of mixed
[3H]DA for 8 min as described above. Nonspecific uptake of each concentration
of [3H]DA (in the presence of 10 µM nomifensine) was subtracted from total
uptake to calculate specific DAT-mediated uptake.
The competitive inhibition of DA uptake by DAT substrate and inhibitors
was examined in intact PC12 cells transfected with WT hDAT or its mutants.
Cells were preincubated in 400 µl KRH buffer containing 50 µl of one of a series
of final concentrations of DA (1 nM-1 mM), GBR12909 (1 nM-10 µM), cocaine (1
nM-1 mM), or ZnCl2 (1, 10, 100 μM) for 10 min at room temperature and then
incubated for 8 min after the addition of 50 µl of [3H]DA (0.05 µM, final
concentration). The reaction for DA uptake in intact cells was terminated by
removing reaction reagents and washing the cells twice with ice cold 1x KRH
buffer. Cells were lysed in 500 μl of 1% SDS for an hour and radioactivity was
measured using a liquid scintillation counter (model Tri-Carb 2900TR;
PerkinElmer Life and Analytical Sciences, Waltham, MA). Vmax and Km were
determined using Prism 5.0 (GraphPad Software Inc., San Diego, CA).
To determine the inhibitory effects of Tat on [3H]DA uptake, cells were
dissociated with trypsin/EDTA (0.25%/0.1%, 1 mL for one 10 cm dish) and
resuspended in culture medium at room temperature. After a 10-min incubation,
the dissociated cells were harvested by centrifugation at 400 × g for 5 min at 4 °C
and washed once with phosphate-buffered saline followed by another
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centrifugation at 400 × g for 5 min at 4 °C. The resulted cell pellets were
resuspended in 1x KRH buffer. Specific [3H]DA uptake was determined in the cell
suspensions prepared from WT hDAT and its mutants in the presence or
absence of recombinant Tat1-86 (Diatheva, Fano, Italy; 140 nM, final
concentration). Cell suspensions were preincubated with Tat for 20 min at room
temperature and then incubated for 8 min after adding [3H]DA (0.05 µM, final
concentration). Non-specific [3H]DA uptake was determined in the presence of 10
µM nomifensine. Incubation was terminated by immediate filtration through
Whatman GF/B glass filters (presoaked with 1 mM pyrocatechol for 3 h). Filters
were washed three times with 3 ml of ice-cold KRH buffer containing
pyrocatechol using a Brandel cell harvester (model M-48; Brandel Inc.,
Gaithersburg, MD). Radioactivity was determined as described above.
2.2.5 [3H]WIN35,428 Binding Assay
Binding assays were conducted to determine whether mutated hDAT
alters the kinetic parameters (Bmax or Kd) of [3H]WIN35,428 binding in intact PC12
cells transfected with WT hDAT or mutants. Cells were washed with sucrosephosphate buffer (final concentration in mM: 2.1 NaH2PO4, 7.3 Na2HPO47H2O,
and 320 sucrose, pH 7.4) and then incubated with one of the six concentrations
of [3H]WIN35,428 (84 Ci/mmol, PerkinElmer, 0.5 – 30 nM final concentrations) in
a final volume of 500 μl on ice for 2 h. In parallel, nonspecific binding at each
concentration of [3H]WIN35,428 (in the presence of 30 µM cocaine, final
concentration) was subtracted from total binding to calculate the specific binding.
For the competitive inhibition experiment, assays were performed in duplicate in
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a final volume of 500 μl. Intact cells transfected with WT hDAT or its mutants
were incubated in buffer containing 50 μl of [3H]WIN35,428 (final concentration, 5
nM) and one of seven concentrations of unlabeled substrate DA (1 nM – 100
μM), cocaine (1 nM – 100 μM), GBR12909 (0.01 nM – 1 μM) or ZnCl2 (1, 10, 100
μM) on ice for 2 h. Assays were terminated by removal of reaction reagents in
well and then washed three times with ice-cold assay buffer. Cells were lysed
with 1% SDS for an hour. Radioactivity was determined as described above.
2.2.6 Cell surface Biotinylation
To determine whether DAT mutations alter DAT surface expression,
biotinylation assays were performed as described previously (Zhu et al. 2005).
PC12 cells transiently expressing hDAT or mutants were plated on 6-well plates
at a density of 105 cells/well. Cells were incubated with 1 ml of 1.5 mg/ml sulfoNHS-SS biotin (Pierce, Rockford, IL) in PBS/Ca/Mg buffer (in mM: 138 NaCl, 2.7
KCl, 1.5 KH2PO4, 9.6 Na2HPO4, 1 MgCl2, 0.1 CaCl2, pH 7.3). After incubation,
cells were washed 3 times with 1 ml of ice-cold 100 mM glycine in PBS/Ca/Mg
buffer and incubated for 30 min at 4°C in 100 mM glycine in PBS/Ca/Mg buffer.
Cells were then washed 3 times with 1 ml of ice-cold PBS/Ca/Mg buffer and then
lysed by addition of 500 ml of Lysis buffer (Triton X-100, 1 µg/ml aprotinin, 1
µg/ml leupeptin, 1 µM pepstatin, 250 µM phenylmethysulfonyl fluoride), followed
by incubation and continuous shaking for 20 min at 4 °C. Cells were transferred
to 1.5 ml tubes and centrifuged at 20,000 × g for 20 min. The resulting pellets
were discarded, and 100 µl of the supernatants was stored at -20 °C for
determination of immunoreactive total DAT. Remaining supernatants were
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incubated with continuous shaking in the presence of monomeric avidin beads in
Triton X-100 buffer (100 µl/tube) for 1 h at room temperature. Samples were
centrifuged subsequently at 17,000 × g for 4 min at 4°C, and supernatants
(containing the non-biotinylated, intracellular protein fraction) were stored at 20°C. Resulting pellets containing the avidin-absorbed biotinylated proteins (cellsurface fraction) were resuspended in 1 ml of 1.0% Triton X-100 buffer and
centrifuged at 17,000 × g for 4 min at 4°C, and pellets were resuspended and
centrifuged twice. Final pellets consisted of the biotinylated proteins adsorbed to
monomeric avidin beads. Biotinylated proteins were eluted by incubating with 75
µl of Laemmli sample buffer for 20 min at room temperature and stored at -20 °C
if further assays were not immediately conducted.
2.2.7 Basal efflux assay
Basal DA efflux was performed at room temperature as described
previously (Midde et al. 2013, 2015). Intact PC12 cells transfected with WT hDAT
or its mutants were preloaded with 0.05 μM [3H]DA for 20 min and then washed 3
times with KRH buffer prior to collecting fractional efflux samples. To obtain an
estimate of the total amount of [3H]DA in the cells at the zero time point, cells
from a set of wells (four wells/sample) were lysed rapidly in 1 % SDS after
preloading with [3H]DA. To collect factional efflux samples, buffer (500 μl) was
added into a separate set of cell wells and transferred to scintillation vials after 1
min as an initial fractional efflux, and another 500 μl buffer was added to the
same wells and collected after 10 min as second fractional efflux. Additional
fractional efflux at 20, 30, 40, 50 min, respectively, was repeated under the same
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procedure. After last fractional efflux, cells were lysed and counted as total
amount of [3H]DA remaining in the cells from each well.
2.2.8 Data analysis
Results are presented as mean ± SEM, and n represents the number of
independent experiments for each experiment group. Kinetic parameters (V max,
Km, Bmax, and Kd ) were determined from saturation curves by nonlinear
regression analysis using a one-site model with variable slope. IC50 values for
substrate and inhibitors inhibiting [3H]DA uptake or [3H]WIN35,428 were
determined from inhibition curves by nonlinear regression analysis using a onesite model with variable slope. For experiments involving comparisons between
unpaired samples, unpaired Student’s t test was used to assess any difference in
the kinetic parameters (Vmax, Km, Bmax, Kd or IC 50) between WT and mutant; logtransformed values of IC50, Km or Kd were used for the statistical comparisons.
Significant differences between samples were analyzed with separate ANOVAs
followed by post-hoc tests, as indicated in the results Section of each
experiment. All statistical analyses were performed using IBM SPSS Statistics
version 20, and differences were considered significant at p < 0.05.
2.3 RESULTS
2.3.1 Computational modeling: His547 and functional relevant residues of human
DAT
Based on the constructed hDAT-Tat binding model in our previous work
(Yuan et al. 2015), both the side chain and backbone of H547 forms a hydrogen
bond with residue R49 of HIV-Tat (Figure 2.1B). The hydrogen bond with the
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H547 side chain is expected to be broken with the H547A mutation, which is
consistent with decreased inhibitory activity of Tat on hDAT-H547A. Based on
the computational model proposed in our previous work (Yuan et al. 2015), the
Y548-Y470-Y551 interaction motif (denoted as the YYY motif) (Figure 2.1C)
could stabilize the first part of transmembrane helix 10 (TM10a) by tying down
residue Y470 with extracellular loop 6. Instability of TM10a could promote the
formation of a salt bridge between D476 (in TM10a) and R85 (in TM1b);
however, the D476-R85 salt bridge would close the “entrance gate” of DA
(Huang and Zhan 2007; Gedeon et al. 2010; Schmitt and Reith 2011; Manepalli
et al. 2012; Midde et al. 2015; Yuan et al. 2015). As a result, instability of TM10a
is expected to block the DA entrance in the outward-open state, which may
decrease the DA uptake efficiency of hDAT. It could be observed that the three
phenol rings in the YYY motif are packed in a specific face to face style, which
indicates that the EL6 should also take a specific conformation for the forming of
the YYY motif. Therefore, any conformation change on EL6 that occurs close to
the YYY motif is expected to regulate the interaction strength of the YYY motif.
As one of the nearest residue to the YYY motif on EL6, residue H547 is an
appropriate candidate for validating our proposed hypothesis. The H547P,
H547A, H547D, and H547R single mutations were tested because proline and
alanine mutations are expected to be the most significant change in backbone
conformation, while aspartic acid or arginine mutation is expected to introduce
significant side-chain conformational disturbances due to their non-neutral
electrostatic potentials. According to the molecular dynamics (MD) simulation
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and the potential of main force (PMF) energy calculation performed in our
previous work (Yuan et al. 2015), we found that the H547A mutation could
enhance the strength of the YYY motif. On the contrary, the H547P mutation
could weaken the strength of the YYY motif, which is consistent with the
increased DA uptake efficiency for the H547A mutant and decreased DA uptake
efficiency for the H547P mutant. Furthermore, the relatively weaker influence of
the H547R and H547D mutations on DA uptake efficiency also support that
backbone conformation of residue 547 plays a key role in the stability of the YYY
motif.
2.3.2 Mutations of His547, Tyr548 and Tyr551 differentially influence DA uptake
kinetics
To determine the functional influence of the His547 (H547A) mutation in
DAT function, kinetic analysis of [3H]DA uptake was performed in PC 12 cells
transfected with WT hDAT or H547A-hDAT. As shown in Figure 2.2A, compared
to WT hDAT (12.43 ± 2.50 pmol/min/10 5 cells), H547A-hDAT displayed a 196%
increase in Vmax value [36.79 ± 7.75 pmol/min/105 cells, t(8) = 2.99, p<0.05,
unpaired Student’s t test] without changes in K m (H547A-hDAT, 3.60 ± 1.46 and
WT hDAT, 1.38 ± 0.36 nM, t(8) = 1.48, p = 0.08). To further determine whether
other substitutions at His547 show differential effects on the basal DA transport,
mutations at this residue (histidine to proline, arginine, and aspartate; H547P,
H547R and H547D) were generated by site-directed mutagenesis. In separate
experiments, the pharmacological profiles of [3H]DA uptake in PC12 cells
transfected with WT hDAT or these mutants were determined. As illustrated in
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Figure 2.3, compared to WT hDAT (11.93 ± 0.72 pmol/min/10 5 cells), Vmax values
were not significantly changed in H547R-hDAT (11.05 ± 0.05 pmol/min/105 cells),
but dramatically decreased in H547P-hDAT [0.16 ± 0.09 nM, t(6) = 6.95, p<0.001]
and H547D-hDAT [4.80 ± 0.18 nM, t(6) = 4.24, p<0.01], respectively. Km values
were not altered in H547P-, H547R-, and H547D-hDAT, compared to WT hDAT.
Besides, kinetic analysis of [3H]DA uptake was performed in PC12 cells
transfected with WT hDAT, Y548H-hDAT, or Y551H-hDAT. As shown in Table
2.1, compared to WT hDAT (13.8 ± 2.8 pmol/min/10 5 cells), the Vmax values were
decreased by 26% in Y548H-hDAT (10.2 ± 2.0 pmol/min/105 cells) and 76% in
Y551H-hDAT [3.3 ± 1.0, t(6) = 3.53, p<0.05]. On the contrary, there was no
significant change in Km in these mutants (Y548H-hDAT, 0.63 ± 0.1, Y551HhDAT, 0.80 ± 0.3, and WT hDAT, 0.55 ± 0.1 μM).
To determine whether the H547A-induced increase in Vmax is associated
with altered subcellular distribution of DAT, biotinylation and immunoblot assays
were performed. Three subcellular fractions were prepared from PC12 cells
transfected with WT hDAT and H547A-hDAT. DAT immunoreactivity in both total
fraction and cell surface fraction (biotinylated) were examined (Figure 2.2B). No
differences between WT hDAT and H547A-hDAT were found in the ratio of
surface DAT (biotinylated DAT) to total DAT (biotinylated/total: WT hDAT, 0.75 ±
0.10; and H547A, 0.97 ± 0.17, t(17) = 1.18. p=0.25), indicating that increased Vmax
in H547A-hDAT is not due to alteration of the available DAT on the cell surface.
With regard to H547P, neither surface nor total DAT signal was detectable (data
not shown). The WIN35,428 binding site shares pharmacological identity with the
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DA uptake carrier (Pristupa et al. 1994). To determine whether other
substitutions at His547 residue alter DA binding sites, kinetic analysis of
[3H]WIN35,428 binding was performed in intact PC12 cells transfected with WT
hDAT, H547P, H547R, or H547D. As shown in Figure 2.3B, in comparison to WT
hDAT, His547 mutants did not alter Bmax values of [3H]WIN35,428 binding.
However, Kd values were increased in H547P [9.29 ± 2.79 pmol/105 cells, t(6) =
2.48, p<0.05], H547R [3.55 ± 0.28 pmol/105 cells, t(6) = 2.65, p<0.05] and H547D
[22.33 ± 7.23 pmol/105 cells, t(6) = 2.76, p<0.05] relative to WT hDAT (2.32 ± 0.37
pmol/105 cells).
2.3.3 Mutations of His547, Tyr548 and Tyr551 differentially alter DA uptake
inhibition potency of substrate and inhibitors
To determine whether mutations of His547, Tyr548, and Tyr551 influence
selective binding sites on hDAT for DA, cocaine, and GBR12909, we tested the
ability of substrate and DAT inhibitors to inhibit [3H]DA uptake in WT hDAT and
its mutants (Table 2.2). In H547A, the apparent affinity (IC50) for DA was
significantly decreased in H547A-hDAT [5356 ± 978 nM, t(15) = 4.3, p<0.05,
unpaired Student’s t test] relative to WT hDAT (1720 ± 206 nM). There were no
changes in the potencies of cocaine and GBR12909 for inhibiting [ 3H]DA uptake
in H547A-hDAT compared to WT hDAT. We also tested whether H547A-hDAT
alters the potencies of DA, cocaine, and GBR12909 for inhibiting [3H]WIN35,428
binding. As shown in Table A.1, the IC50 value of cocaine for inhibiting DA uptake
was decreased in H547A-hDAT [156 ± 36 nM, t(8) = 2.70, p<0.05] compared to
WT hDAT (308 ± 55 nM). However, H547A-hDAT did not alter the potencies of
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DA and GBR12909 for inhibiting DA uptake. We determined whether H547P,
H547R, and H547D differentially alter the potencies of DA, cocaine, and
GBR12909 for inhibition of [3H]DA uptake (Table 2.2). The apparent affinity (IC50)
for DA was significantly increased in H547P-hDAT [300 ± 49 nM, t(15) = 4.30,
p<0.001], compared to the respective WT hDAT control (DA, 1720 ± 206 nM). No
changes were observed in the potencies of cocaine and GBR12909 in H547P-,
H547R-, and H547D-hDAT for inhibiting [3H]DA uptake compared to WT hDAT.
In Y548H-hDAT and Y551H-hDAT, the affinity for DA was increased in Y551H
[663 ± 70 nM, t(17) = 2.60, p<0.001] relative to WT hDAT (1720 ± 206 nM) while
Y548H showed no change. In addition, the affinity for cocaine was increased in
Y548H [77 ± 9 nM, t(17) = 3.80, p<0.01], and Y551H [59 ± 7 nM, t(17) = 4.10,
p<0.001], respectively, relative to WT hDAT (294 ± 34 nM).
2.3.4 Mutations of His547 attenuate Tat-induced inhibition of DA transport
Based on our computational prediction, it could be expected that
mutations of His547 would eliminate a hydrogen bond between D-H547 and TR49 (Figure 2.1), impairing Tat binding on hDAT, thereby inducing an attenuation
of Tat-induced inhibition of DA uptake. We examined the specific [3H]DA uptake
in WT hDAT and the His547 mutants in the presence or absence of recombinant
Tat1-86. Due to the difference in the specific [3H]DA uptake in WT hDAT and H547
mutants was shown in Figures 2.2 and 2.3, the inhibitory effect of Tat on DAT
function in WT, H547A, H547P, H547R, H547D, and Y551H were presented as
the ratio of Tat-mediated [3H]DA uptake to their respective controls (in the
absence of Tat, Figure 2.4). One-way ANOVA revealed a significant main effect
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of genotype [F(3, 28) = 5.72; p<0.01]. Post hoc analysis showed that Tat (140 nM,
final concentration) produced a 31% decrease in the specific [3H]DA uptake in
WT hDAT relative to its control [in DPM: Tat (4794 ± 989) vs control (6858 ±
1393), t(7) = 5.03, p<0.01]; however, no effect of Tat on DA uptake was observed
in H547A [in DPM: Tat (6190 ± 1474) vs control (5799 ± 1408)], H547R [in DPM:
Tat (5026 ± 1097) vs control (4698 ± 1257)], H547D [in DPM: Tat (2159 ± 557) vs
control (2021 ± 565)], and Y551H [in DPM: Tat (662 ± 107) vs control (642 ±
108)] (ps > 0.01, Bonferroni t-test), suggesting that mutations of H547 attenuate
Tat-induced inhibition of DA uptake.
2.3.5 Effects of H547A and H547D on Zinc regulation of DAT conformational
transitions and basal DA efflux
We have demonstrated that Tat protein regulates DA transport
allosterically (Zhu et al. 2009, 2011). To determine whether His547 residue acts
as a potential site for the allosteric modulation of hDAT-Tat interaction, we
examined the effects of the respective mutations of His547 on Zn 2+ modulation of
[3H]DA uptake and [3H]WIN35,428 binding. In general, the conformational
changes in DA transport processes involve conversions between outward- and
inward-facing conformations (Zhao et al. 2010). Occupancy of the endogenous
Zn2+ binding site in WT hDAT stabilizes the transporter in an outward-facing
conformation, which allows DA to bind but inhibits its translocation, thereby
decreasing DA uptake (Loland et al. 2003) but increasing [3H]WIN35,428 binding
(Norregaard et al. 1998). Addition of Zn2+ is able to partially reverse an inwardfacing state to an outward-facing state (Norregaard et al. 1998; Loland et al.
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2003). On the basis of this principle, the addition of Zn 2+ to WT hDAT would
inhibit DA uptake, whereas in a functional mutation in DAT Zn 2+ might diminish
the preference for the inward-facing conformation and thus enhance DA uptake.
As shown in Figure 2.5, two-way ANOVA on the specific [3H]DA uptake in WT
and H547A-hDAT and H547D-hDAT revealed a significant main effect of zinc
[F(3,

48)

= 51.1; p<0.001] and a significant mutation × zinc interaction [F(6,

48)

=

4.90; p<0.01]. The addition of Zn2+ significantly decreased [3H]DA uptake in WT
and mutants in a zinc concentration-dependent manner (Figure 2.5A). Compared
to control (in absence of Zn2+), the addition of Zn2+ (100 µM) decreased [3H]DA
uptake in WT (37%), H547A-hDAT (38%) and H547D-hDAT (60%), respectively
(ps< 0.01, unpaired Student’s t test), suggesting these mutants do not affect the
highest concentration of Zn2+-mediated regulation of DA transport. However, the
addition of Zn2+ (10 µM) decreased [3H]DA uptake in WT (25%) and H547DhDAT (53%), respectively (ps< 0.01, unpaired Student’s t test) but not in H547AhDAT (10%), suggesting an attenuation of Zn 2+-mediated regulation of DA
transport by H547A-hDAT. In contrast, as shown in Figure 2.5B, a two way
ANOVA on the specific [3H]WIN35,428 binding in WT and H547A and H547D
revealed significant main effects of mutation [F(2, 12) = 5.55; p<0.05], zinc [F(3, 36) =
19.19; p<0.001] and a significant mutation × zinc interaction [F(6,
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= 7.76;

p<0.001]. The addition of Zn2+ (10 and 100 µM, final concentration) significantly
increased [3H]WIN35,428 binding in WT hDAT (10 µM, 80% and 100 µM, 82%)
and H547A-hDAT (100 µM, 27%), respectively. The Zn 2+ (10 and 100 µM)-
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induced increase in [3H]WIN35,428 binding was significantly diminished in
H547A-hDAT and H547D-hDAT.
To further determine the effects of His547 mutants on transporter
conformational transitions, we examined the basal efflux levels of [ 3H]DA in WT
hDAT, H547A-hDAT, and H547D-hDAT. With regard to H547A-hDAT (Figure
2.5C), after preloading with 0.05 µM [3H]DA for 20 min at room temperature,
PC12 cells transfected with WT hDAT and H547A-hDAT were washed and
fractional DA efflux samples were collected at the indicated time. Two-way
ANOVA on the basal efflux of [3H]DA indicated a significant main effect of time
[F(5, 30) = 115.59; p<0.001]. No significant main effects of mutation and mutation ×
time interaction were found. With regard to H547D-hDAT (Figure 5D), a two-way
ANOVA on the basal efflux of [3H]DA revealed significant main effects of
mutation [F(1,

8)

= 17.38; p<0.01] and time [F(5,

40)

= 252.09; p<0.001] and

mutation × time interaction [F(5, 40) = 11.39; p<0.001]. Post-hoc analyses showed
that compared to WT hDAT, DA efflux levels were elevated at 1 and 10 min in
H547D-hDAT (ps<0.05, Bonferroni t-test).
2.3.6 Effects of H547A on basal PKC-mediated regulation of DAT function
To determine whether H547A-induced enhancement of Vmax is associated
with basal levels of DAT phosphorylation, kinetic analysis of [ 3H]DA uptake was
performed in WT and H547A-hDAT in the presence or absence of a PKC
activator phorbol 12-myristate 13-acetate (PMA). As shown in Figure 2.6, a twoway ANOVA on the Vmax values revealed significant main effects of mutation [F(1,
32)

= 14.67; p<0.001] and PMA treatment [F(1, 32) = 13.31; p<0.001] and mutation
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× PMA treatment interaction [F(1, 32) = 4.8; p<0.05]. In the absence of PMA, the
Vmax [3H]DA uptake was higher in H547A-hDAT than WT [F(1, 16) = 10.69; p<0.01].
The addition of 1 µM PMA produced a 40% and 60% decrease in the V max in WT
and H547A-hDAT, respectively, compared to the respective control [F(1,

16)

=

4.43; p<0.05]. With regard to the Km values, two-way ANOVA revealed significant
main effects of mutation [F(1, 32) = 20.73; p<0.001] and PMA treatment [F(1, 32) =
7.36; p<0.05]. No significant mutation × PMA treatment interaction [F(1, 32) = 3.62;
p = 0.066] was found. Post hoc tests showed that the Km value was lower in WT
hDAT (2.18 ± 0.24) than H547A-hDAT [7.89 ± 1.30, t(15) = 4.06; p< 0.01] in the
absence of PMA. After addition of PMA, the Km value was still lower in WT hDAT
(1.89 ± 0.23) than H547A-hDAT [4.08 ± 0.88, t(15) = 4.06; p< 0.01], however,
PMA significantly decreased Km values in H547A-hDAT [4.08 ± 0.88 µM, t(16) =
2.42; p< 0.05] but not in WT hDAT (p>0.05) compared to the respective control.
In a separate experiment, we determined the specific [3H]DA uptake in the
WT and H547 mutants in the presence or absence of a PKC inhibitor
bisindolylmaleimide-I (BIM).

As shown in Figure 2.6 (C and D), a two-way

ANOVA on the Vmax values revealed significant main effects of mutation [F(1, 20) =
14.24; p<0.01] and BIM treatment [F(1,

20)

= 4.55; p<0.05]. No significant

interaction of mutation × BIM treatment was observed. Addition of 1 µM BIM
produced a 98% increase in the Vmax in WT [F(1,

10)

= 6.96; p<0.05] but not in

H547A relative to their controls. The Km value was lower in WT hDAT (0.65 ±
0.07) than H547A-hDAT [1.37 ± 0.31, t(10) = 2.24; p< 0.05] in the absence of BIM.

41

This difference was not observed between WT hDAT and H547A-hDAT after
BIM.
2.4 DISCUSSION
Our recent computational-experimental study demonstrated that an
alanine mutation to hDAT His547 (H547A) plays a crucial role in the hDAT-Tat
binding and DA uptake by hDAT (Yuan et al. 2016b). The present study aims to
pharmacologically characterize His547 and its functional influence in Tat-induced
inhibition of DA uptake. There were two main findings. First, H547A enhances
DA transport in a PKC-dependent manner, and other substitutions of His547
(H547P, H547R, H547D) differentially altered DA uptake. Second, Tat inhibited
DA uptake in WT hDAT, which was attenuated in His547 mutants. In addition,
H547A attenuated zinc ion modulation of [3H]DA uptake and [3H]WIN35,428
binding, indicating that H547A leads to altered conformational transporter
transitions. Overall, these results suggest potential therapeutic effects of
targeting hDAT His547 on Tat-induced dysfunction of dopaminergic transmission
observed in HAND patients.
Both His547 and the YYY motif (Tyr548-Tyr470-Tyr551) are found in the
extracellular loop 6 (EL6) region of DAT. There was no significant change in the
YYY motif structure unit during the conformational conversion of hDAT from the
outward-open state to the outward-occlude state and then to the inward-open
state, according to our computational simulation (Yuan et al. 2016b). This
observation suggests the possibility of promoting hDAT activity by increasing the
stability of EL6 via enhancing the strength of the YYY motif (Yuan et al. 2016b).
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Y470H mutation is expected to destabilize the YYY motif by impairing both the
Y470-Y548 and Y470-Y551 interactions, whereas Y548H and Y551H mutations
are expected to partially reproduce the effect of Y470H, as they only impair one
of the Y470-Y548 and Y470-Y551 interactions. The Y470H mutant was reported
to retain only ~18% [17.8%(Midde et al. 2013),17.7%(Yuan et al. 2016b) in our
previous reports] Vmax compared to WT hDAT, whereas the present study shows
that Y548H and Y551H mutants retain 24% and 74% V max compared to WT
hDAT, respectively (Table 2.1). Interestingly, based on the YYY motif model, the
combined effect of the Y548H and Y551H mutations may be expected to retain
18% (24%×74%) Vmax compared to WT hDAT, which is consistent with the effect
of the Y470H single mutation on Vmax. This observation confirms our
computational prediction that the YYY motif could stabilize the critical
transmembrane 10 (TM10) by tying down Tyr470 with EL6 for enhanced
transporter stability (Yuan et al. 2016b). Disrupting this motif will result in the
perturbation of transport function, as evidenced by the decrease in Vmax in the
mutants Y548H, Y470H, and Y551H. According to our previous work (Midde et
al. 2013, 2015; Yuan et al. 2015), the center residue of YYY motif , i.e., residue
Y470, is critical for Tat-induced inhibition of DA uptake, which indicates that
stability of the YYY motif is also involved in hDAT/Tat binding. Thus, mutating
tyrosine551 to histidine may not only change the transporter’s capacity for uptake
but also inflict a structural change of hDAT/Tat binding. Our results show that the
Y551H mutation attenuates Tat-induced inhibition of DA uptake (Figure 2.4),
which is also consistent with our computational model.
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To investigate the effect of the H547 mutation on influencing the YYY
motif and hDAT transport, experiments were performed to obtain the kinetics
data for four mutations, including H547A, H547P, H547R, and H547D. Alanine
has the highest helix propensity, on the contrary, proline and glycine are
generally known as “helix breakers” (O’Neil and DeGrado 1990; Pace and
Scholtz 1998). Therefore, H547A and H547P mutations suggest two distinct
directions of disturbing the backbone conformation. Besides, mutation to other
residues such as arginine or aspartic acid would introduce the most significant
side-chain disturbance. Consequently, the H547R and H547D mutations would
be reasonable probes for investigating the role of the side chain of residue 547.
The present study shows that an alanine mutation on His547 increases the Vmax
by ~3-fold compared to WT hDAT, indicating that H547A is a critical residue that
mediates the enhancement of DA transport, which supports our computational
prediction (Yuan et al. 2016b). Furthermore, the H547A-induced enhancement of
DA uptake was not observed in other substitutions of H547, in which V max was
significantly decreased in H547P but not altered in H547R, whereas the effect of
the H547D mutation on Vmax is relatively weaker than that of the H547P mutation.
The hDAT activity shows higher sensitivity to backbone disturbances induced by
H547A or H547P rather than side chain disturbances induced by H547D or
H547R. Furthermore, the distinct helix propensity of H547A and H547P
correspond to the up-regulation and down-regulation of hDAT activity. Thus, the
backbone conformation of residue His547 is expected to play an important role in
hDAT function, which also supports our proposed hypothesis based on
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computational prediction (Yuan et al. 2016b). Notably, the baseline Km values for
WT hDAT vary in the current study, which may be affected by the experimental
conditions and individual experiments performed across different times. For
example, the Km values are relatively higher in either WT or H547A in Figure
2.6B than others; this is because PMA-mediated DA uptake assay was
conducted at 37 °C. Previous studies have reported that DAT expression in
plasma membrane is increased in a temperature-dependent manner (Loder and
Melikian 2003), which may cause increased Vmax and decreased Km for DA
uptake. However, the Km value of H547A hDAT was always compared to its
respective WT hDAT control within each individual experiment. Importantly, our
results demonstrate that H547A-hDAT displays an increased Km value for DA
uptake relative to WT hDAT, indicating that mutating the His547 residue may
alter the binding site of substrate DA. Given that DA transport efficiency by DAT
is largely governed by surface DAT expression (Zhu and Reith 2008), our results
show that mutations of these residues do not alter either cell surface DAT
expression or [3H]WIN35,428 binding sites in intact cells expressing these
mutants, indicating that the altered Vmax in these mutants is not due to changing
surface DAT expression. Interestingly, mutant H547P displays a dramatic
decrease in DA uptake, which is accompanied by decreased total DAT
expression (data not shown). Considering that site-directed mutagenesis studies
on DAT typically result in a decrease in DA uptake (Chen and Reith 2000; Loland
et al. 2001; Midde et al. 2013, 2015), the enhancement of DA transporter as
evidenced by the H547A mutant suggest that targeting this residue may provide
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an exciting knowledge basis for the development of novel concepts for
therapeutic treatment of HAND.
Consistent with our previous reports (Midde et al. 2013, 2015), the current
results show that mutations of His547 completely eliminate the inhibitory effect of
Tat on DA transport, further suggesting that the Tat molecule is associated with
DAT through intermolecular electrostatic attractions and complementary
hydrophobic interactions. Our computational study predicts that the side chain of
H547 forms hydrogen bond with residue R49 of HIV-Tat and that alanine
mutation of H547 would be expected to change the local backbone conformation
of hDAT-H547 and eliminate the hydrogen bond between hDAT-H547A/Tat-R49
(Figure 2.1). These findings indicate the important role of His547 in Tat-DAT
interaction. The allosteric modulation of DAT is responsible for conformational
transitions via substrate- and ligand-binding sites on DAT (Zhao et al. 2010;
Shan et al. 2011). Given that Tat protein regulates DAT function allosterically
(Zhu et al. 2009, 2011), we tested whether mutated His547 attenuates Tat effect
through a conformational transporter transition. First, our results show that
H547A and H547D attenuate zinc-mediated decrease in DA uptake and increase
in WIN binding. Second, H547D but not H547A enhances basal DA efflux, which
further supports our previous report showing Tat protein enhancing DA efflux in
WT hDAT (Pascoli et al. 2011). These results are consistent with our previous
reports (Midde et al. 2013, 2015), suggesting that disrupting the intermolecular
interaction of Tat and DAT influences Tat-induced inhibition of DA uptake.
Further understanding the functional relevance of additional residues in Tat for
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DAT modulation

will provide

useful feedback for further refining

the

computationally predicted binding model of DAT with Tat.
An important finding from the current study is that promoting PKC
phosphorylation of DAT with PMA resulted in 40% and 60% reduction of DA
uptake in WT hDAT and H547A, respectively. Similarly, preventing PKC
phosphorylation of DAT with BIM produces a 98% and 42% increase in DA
uptake in WT hDAT and H547A, respectively. This suggests a differential
sensitivity to PMA- or BIM-induced activation or inhibition of DAT function
between WT and H547A. It has been well characterized that PKC-dependent
phosphorylation of DAT regulates DA uptake velocity (Vaughan et al. 1997; Zhu
et al. 1997; Huff et al. 2002). One possibility is that mutation of His547 alters
basal levels of PKC-mediated phosphorylation of DAT, thereby resulting in the
enhanced DA uptake. Recent studies demonstrate that the serine7 (S7) DAT
residue is critical for PKC-dependent DAT phosphorylation (Moritz et al. 2013),
and the alanine mutation of S7 results in an increase in DA uptake relative to WT
DAT (Moritz et al. 2015). As the PKC phosphorylation sites on cytoplasmic
domain (intracellular side) of hDAT are structurally far away from the residue
H547 on the extracellular side of hDAT (Midde et al. 2013; Yuan et al. 2016b),
the H547A mutation is likely to regulate the PKC-mediated phosphorylation by
allosteric effect. Therefore, future studies will be necessary to investigate the
double mutant S7A/H547A as an approach to identify the site of reduced PKC
phosphorylation is on H547A-hDAT.
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The current finding showing an unusual hDAT mutant capable of both
enhancing DA transport and preventing Tat inhibitory effect on DAT is of general
interest in therapeutic treatment of drug addiction. The interplay of Tat and
cocaine augments synaptic DA levels and Tat release by inhibiting DAT activity
(Zhu et al. 2009; Ferris et al. 2010), which may contribute to the progression of
HAND underlying the cognitive deficits in HIV-1 positive cocaine-using individuals
(Wang et al. 2004; Chang et al. 2008). Similarly, conditioned expression of Tat in
the mouse brain further potentiates cocaine rewarding in vivo (Paris et al. 2014).
Together, these results suggest a synergistic effect of cocaine and Tat on DA
transmission contributing to cognitive dysfunction and elevating the cocaine
addictive effects. The current findings might provide novel insight into developing
small molecule compounds that could bind to the unique residue on hDAT
(His547), thereby not only preventing Tat interaction with DAT but also
enhancing DA transport function. Ideally, the effectiveness of early intervention
for HAND may combine such compound(s) with anti-retroviral therapy, which
would be beneficial to the preservation of neurocognitive function in HIV-infected
individuals.
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Table 2.1 Kinetic properties of [3H]DA uptake in WT hDAT, Y548H-hDAT and
Y551H-hDAT

Vmax (pmol/min/105 cells)

WT hDAT

Km (µM)

13.8 ± 2.8

0.55 ± 0.1

Y548H

10.2 ± 2.0

0.63 ± 0.1

Y551H

3.3 ± 1.0*

0.80 ± 0.3

* p<0.05 compared with WT hDAT
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Table 2.2 Summary of inhibitory activities in [3H]DA uptake assay in WT and
mutated hDAT in the presence of DA, cocaine and GBR12909

IC50 (nM)

WT
hDAT

H547A

H547P

H547R

H547D

Y548H

Y551H

DA

1720
±206

5356 ±
978*

300 ±
48*

2454
±366

1168
±154

1744 ±
105

663 ±
70*

Cocaine

294 ± 34

338 ± 26

238 ±
26

470 ±
33

198 ± 32

77 ± 9*

59 ± 7*

GBR12909 262 ± 42

270 ± 85

332 ±
98 ± 17 344 ± 18 162 ± 44 279 ±
13
46
Data are presented as mean ± S.E.M. values from five to seven independent
experiments performed in duplicate. * p<0.05 compared with WT hDAT (unpaired
Student’s t test)
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Figure 2.1 (A) Computational model of human dopamine transporter (hDAT) and HIV-1
Tat binding. hDAT and Tat are represented as cyan surface and golden ribbon,
respectively. (B) A local view of DAT residue H547 and its direct interaction with Tat
residue R49, hDAT is represented as a cyan ribbon. The residues are represented in
sticks, with hydrogen bonds between the two residues represented with dashed lines
labeled with their corresponding coordination distances. (C) Structural details of the
residues Y470, Y551, H547, D476, and R85 on hDAT. hDAT is represented as a cyan
ribbon, while the first part of transmembrane helix 10 (TM10a) and extracellular loop 6
(EL6) are colored in green and orange, respectively. Dopamine is represented as a balland-stick molecule in purple. Hydrogen bonds between D476 and R85 are indicated by
dashed lines with coordinating distances labeled.
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Figure 2.2 DA transport and DAT surface expression in WT hDAT and mutant. (A)
Kinetic analysis of [3H]DA uptake in WT hDAT and H547A-hDAT. PC12 cells transfected
with WT hDAT or H547A-hDAT were incubated with one of 6 mixed concentrations of
[3H]DA as total rate of DA uptake. In parallel, nonspecific uptake of each concentration of
[3H]DA (in the presence of 10 µM nomifensine, final concentration) was subtracted from
total uptake to calculate DAT-mediated uptake. The Vmax and Km values were estimated
by fitting the data to the Michaelis-Menten equation and represent the means from five
independent experiments ± S.E.M. * p < 0.05 compared to control value (unpaired
Student’s t test) (n = 5). (B) Cell surface expression of WT hDAT and H547A-hDAT was
analyzed by biotinylation assay. Top panel: representative immunoblots (see Appendix
A) of PC12 cells expressing WT hDAT (WT) or H547A-hDAT (H547A) (n=9).
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Figure 2.3 DA transport and DAT surface binding sites in WT hDAT and H547
substitutional mutants. (A) Kinetic analysis of [3H]DA uptake in WT hDAT and mutants.
The Vmax and Km values were estimated by fitting the data to the Michaelis-Menten
equation and represent the means from five independent experiments ± S.E.M. * p <
0.05 compared to WT hDAT value (unpaired Student’s t test) (n = 5). (B) Saturation
binding of [3H]WIN35,428 in intact PC12 cells transfected with WT hDAT and mutants.
The Bmax and Kd values were estimated by fitting one-site binding and represent the
means from four independent experiments ± S.E.M. * p < 0.05 compared to control value
(unpaired Student’s t test) (n = 4).
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Figure 2.4 Effects of Tat on kinetic analysis of [3H]DA uptake in WT hDAT and His547
mutants. PC12 cells transfected with WT hDAT (WT), H547A-hDAT (H547A), H547RhDAT (H547R), H547D-hDAT (H547D), or Y551H-hDAT (Y551H) were preincubated
with or without recombinant Tat1-86 (rTat1-86) (140 nM, final concentration) at room
temperature for 20 min followed by the addition of [ 3H]DA. Nonspecific uptake was
determined in the presence of 10 µM final concentration of nomifensine. Data are
expressed as the ratio of the specific [3H]DA uptake in the presence of Tat to that in the
absence of Tat [in DPM: WT hDAT (Tat, 4794 ± 989 vs control, 6858 ± 1393); H547A
(Tat, 6190 ± 1474 vs control, 5799 ± 1408); H547R (Tat, 5026 ± 1097 vs control, 4698 ±
1257); H547D (Tat, 2159 ± 557 vs control, 2021 ± 565); and Y551H (Tat, 662 ± 107 vs
control, 642 ± 108)] n=7-8. * p < 0.05 compared with WT hDAT control values.
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Figure 2.5 Effects of H547A and H547D mutants on transporter conformational
transitions. Mutations of His547 affect zinc regulation of [ 3H]DA uptake (A) and
[3H]WIN35,428 binding (B). PC12 cells transfected with WT hDAT (WT), H547A-hDAT
(H547A) and H547D-hDAT (H547D) were incubated with KRH buffer alone (control) or
ZnCl2 (1, 10, 100 µM, final concentration) followed by [ 3H]DA uptake or [3H]WIN35,428
binding (n = 5-7). The histogram shows [3H]DA uptake and [3H]WIN35,428 binding
expressed as mean ± S.E.M. of the respective controls set to 100% for the mutant. * p <
0.05 compared to control. # p < 0.05 compared to WT hDAT with ZnCl 2. Functional DA
efflux of DA properties of H547A-hDAT (C) and H547D-hDAT (D) with their respective
WT hDAT control. PC12 cells transfected with WT hDAT or mutants were preincubated
with KRH buffer containing [3H]DA (0.05 µM, final concentration) at room temperature for
20 min. After incubation, cells were washed and incubated with fresh buffer as indicated
time points. Subsequently, the buffer was removed from cells, and radioactivity in the
buffer and remaining in the cells was counted. Each fractional efflux of [ 3H]DA in WT
hDAT (WT) or mutants was expressed as percentage of total [ 3H]DA in the cells at the
start of the experiment. Fractional [3H]DA efflux levels at 1, 10, 20, 30, 40 and 50 min are
expressed as the percentage of total [3H]DA with preloading with 0.05 µM (WT hDAT:
13743 ± 3050 dpm, H547A-hDAT: 14464 ± 2547 dpm and H547D-hDAT: 1891 ± 428
dpm) presented in the cells at the start of the experiment (n = 4). ×× p < 0.05 compared
to WT hDAT (Bonferroni t-test).
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Figure 2.6 Effects of H547A on basal PKC-mediated regulation of DAT function. Kinetic
analysis of [3H]DA uptake in PC12 cells transfected with WT hDAT or H547A-hDAT in
the presence or absence of PKC activator PMA (1 µM) (A and B) or inhibitor BIM (1 µM)
(C and D). * p< 0.05 compared to their respective controls. # p< 0.05 compared to WT
hDAT (n = 6-9).
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CHAPTER 3

MUTATIONS ON THE HUMAN DOPAMINE TRANSPORTER AT
TYROSINE88, ASPARTIC ACID206, AND HISTIDINE547
INFLUENCE TRANSPORTER FUNCTION AND ATTENUATE TATINDUCED INHIBITION OF DOPAMINE UPTAKE 2

2

Quizon, P. M., Zhu, Y., Zhou, Y., Yuan, Y., Strauss, M. J., Sun, W. L., Zhan, C. G., & Zhu, J.
(2019). Mutations on the human dopamine transporter at tyrosine88, aspartic acid206, and
histidine547 influence transporter function and attenuate Tat-induced inhibition of dopamine
uptake. In preparation to be submitted to the Journal of Biological Chemistry.
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ABSTRACT: Dopamine transporter (DAT)-mediated dopamine reuptake is
critical for normal dopamine homeostasis. HIV-1 transactivator of transcription
(Tat) has a major impact on the development of HIV-1 associated neurocognitive
disorders through its direct inhibition of DAT. The current study determined the
effects

of

single

(D206L,

D381L),

double

(D206L/H547A),

and

triple

(Y88F/D206L/H547A) mutants of human DAT (hDAT) on basal dopamine
transport and Tat-induced inhibition of dopamine uptake. Compared to wild-type
hDAT, the maximal velocity (Vmax) of [3H]dopamine was decreased in D381L and
Y88F/D206L/H547A, increased in D206L/H547A, and unaltered in D206L.
Recombinant Tat1-86 induced a 30% reduction of dopamine uptake in wild-type
hDAT, which was attenuated in D206L, D206L/H547A, and Y88F/D206L/H547A.
Introducing mutations on Tat1-86 (K19A and C22G) disrupted Tat inhibition,
demonstrating perturbed Tat-DAT interaction. Differential effects of DAT mutants
on transporter conformation were evidenced by attenuation of zinc-induced
increased [3H]WIN35,428 binding in D206L/H547A and Y88F/D206A/H547A and
enhanced basal MPP+ efflux in D206L/H547A, suggesting that both D206 and
H547 are critical in transport stabilization. It was then determined whether the
H547A-induced increase in DA uptake is due to conformational alterations by
inserting a cysteine in position 159 on a cysteine-insensitive hDAT background.
In combination with the H547A mutation (E2C-I159C/H547A), the addition of
MTSET increased accessibility to the inserted cysteine while decreasing
dopamine uptake, indicative of an outward-open conformation. H547A showed
altered palmitoylation, which may contribute to its enhanced V max. These results
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indicate that the mutants generated from Y88F, D206L, and H547A attenuate Tat
inhibition while preserving DA uptake, providing insights into identifying targets
for improving DAT-mediated dopaminergic dysregulation.
3.1 INTRODUCTION
HIV-1 continues to affect an estimated thirty-seven million people
worldwide. Despite advances in combined antiretroviral therapy, more than 50%
of HIV-1 positive individuals suffer from HIV-associated neurocognitive disorders
(HAND), a variety of neuropsychological complications that range from mild
impairment to severe dementia (Heaton et al. 2011; Clifford and Ances 2013).
Patients with HAND exhibit cognitive deficits as well as functional impairment in
activities of daily living (Clifford and Ances 2013). Because antiretroviral
medications

cannot

efficiently

cross

the

blood-brain

barrier,

chronic

neuroinflammation and neurotoxicity induced by HIV-1 viral proteins that are
shed from infected monocytes that enter the brain eventually lead to the
development of HAND (Ensoli et al. 1993; Sulzer et al. 2005; King et al. 2006;
Rayne et al. 2010). Due to the degenerative and irreversible nature of these
disorders, early intervention is critical; however, there are currently no promising
therapeutic strategies for the treatment of HAND.
Dopamine (DA) is involved in the control of reward, attention, motivation,
and cognition centers of the brain. The dopamine transporter (DAT) regulates DA
levels through a reuptake mechanism that rapidly sequesters extracellular DA
back into the presynaptic neuron (Torres et al. 2003; Torres 2006). However, in
HIV-infected patients, the HIV-1 viral protein Tat (transactivator of transcription)
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directly inhibits DAT (Zhu et al. 2011; Yuan et al. 2015), leading to DA overflow
that further stimulates viral replication and protein release in infected cells
(Gaskill et al. 2009; Nolan and Gaskill 2019), eventually accelerating HAND
pathogenesis. Targeting the Tat-DAT interaction during the early stages of HIV-1
infection is therefore a potential therapeutic strategy to prevent the development
of HAND.
It has been recently reported that the amino acid residues tyrosine88
(Y88), lysine92 (K92), aspartic acid206 (D206), and histidine547 (H547) of
human DAT (hDAT) are critical to Tat-DAT binding, as mutations on these
residues attenuated Tat-induced inhibition of DA uptake while differentially
affecting transporter function (Bucci 2015; Midde et al. 2015; Yuan et al. 2015,
2016b; Quizon et al. 2016). For instance, point mutations Y88F and D206L
preserved basal DA uptake activity; K92M decreased DA uptake (Midde et al.
2015). Interestingly, H547A dramatically increased DA uptake by 196% (Quizon
et al. 2016). Mutational analysis with hDAT constructs that bear point mutations
on these key binding sites only reflect the properties of single residues. In order
to account for the complex interactions between key residues involved in TatDAT binding, mutants Y88F/H547A and Y88F/K92M/H547A were generated.
Y88F/H547A preserved the DA uptake enhancement observed in single mutant
H547A, while Y88F/K92M/H547A dramatically decreased DA uptake (Sun et al.
2019). Y88F/H547A attenuated the inhibitory effects of Tat on DA uptake as
well, suggestive of the key role of Y88 and H547 in DAT function as well as TatDAT interaction (Sun et al. 2019). To further delve into the interactions between
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key

recognition

binding

residues,

other

combined

mutant

constructs

D206L/H547A and Y88F/D206L/H547A were generated and their effects on
transporter function, conformation, and Tat-induced inhibition of DA uptake were
characterized. A mutation on the Tat protein at position 19 (lysine19 to alanine,
K19A) was also generated to further demonstrate the key interaction between
Y88 on DAT with K19 on Tat.
Lastly, in order to determine whether the dramatic increase in DA uptake
in H547A is due to conformational alterations, posttranslational modifications
such as palmitoylation, or a combination of both, two experiments were utilized:
the substituted cysteine accessibility method using sulfhydryl-reactive and
positively charged agent MTSET ([2-(trimethylammonium) ethyl] methane
thiosulfonate; MTSET assay) and the 2-BP assay, which uses palmitoylation
inhibitor 2-bromopalmitate (2-BP). The MTSET tested whether an engineered
cysteine in position 159 in the H547A mutant renders the transporter more
reactive to inactivation to MTSET. Previous reports studying changes in DAT
conformation demonstrated that the accessibility of the inserted cysteine in
position 159 to MTSET was highly dependent upon whether the transporter was
in an outward- or inward-facing conformation (Loland et al. 2003, 2004; Pedersen
et al. 2014). Accessibility of MTSET to the homologous norepinephrine
transporter’s (NET) and serotonin transporter’s (SERT) corresponding residues
(155 and 179, respectively) was also observed to be indicative of conformational
state (Chen and Rudnick 2000), suggesting that the substituted cysteine
accessibility method may be used in probing alterations to the conformational
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equilibrium in other monoamine transporters. The 2-BP assay pharmacologically
tested whether H547A exhibited a greater sensitivity to palmitoylation inactivation
by 2-BP compared to WT. It has been previously reported that DAT kinetics is
regulated by both phosphorylation and palmitoylation in a reciprocal manner: that
is, an increase in phosphorylation results in a decrease in palmitoylation and
vice-versa (Moritz et al. 2015).

Because it has been recently reported that

H547A enhanced DAT uptake in a PKC-dependent manner (Quizon et al. 2016),
it was then tested whether this is true for palmitoylation as well.
This study reveals how multiple mutations on DAT and a point mutation on
Tat affect Tat-DAT binding. The current study demonstrates how the H547A
mutation enhances DAT uptake through a combination of conformational
alterations and posttranslational modifications. These results will aid in the
development of therapies that target Tat-DAT binding in order to prevent
neurocognitive dysfunction in patients infected with HIV-1.
3.2 MATERIALS AND METHODS
3.2.1 Predicting the site for hDAT binding with Tat
The binding structure of hDAT with HIV-1 clade B type Tat was modeled
and simulated based on the nuclear magnetic resonance (NMR) structures of Tat
(Péloponèse et al., 2000) and the constructed structure of the hDAT-DA complex
(Midde et al., 2015; Yuan, Huang, et al., 2016). Protein docking method and
molecular dynamics simulation were employed to identify the conformation of
hDAT-Tat complex. The energy-minimized complex structure used in this work
was extracted from long-time equilibrated molecular dynamics simulation
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trajectories in previous reports (Midde et al., 2015; Quizon et al., 2016; Yuan et
al., 2015; Yuan, Huang, et al., 2016; Yuan, Quizon, et al., 2016).
3.2.2 Construction of plasmids
Mutants on hDAT were generated from the computational modeling
predictions as described previously using site-directed mutagenesis based on the
wild-type hDAT (WT hDAT) sequence (NCBI, cDNA clone MGC: 164608 IMAGE:
40146999) (Midde et al., 2015; Quizon et al., 2016; Yuan, Huang, et al., 2016;
Yuan, Quizon, et al., 2016). The combination of hDAT mutations on Asp206 and
His547 (Aspartic acid 206 to leucine and histidine 547 to alanine, D206L/H547A)
were predicted to eliminate two hydrogen bonds between Tat and hDAT. On the
other hand, the combination of mutations on Tyr88, Asp206, and His547
(tyrosine88 to phenylalanine and aspartic acid 206 to leucine and histidine 547 to
alanine, Y88F/D206L/H547A) were predicted to eliminate three hydrogen bonds
from the Tat-hDAT complex. E2C mutants on hDAT used for the MTSET assay
were generated based on the same WT hDAT sequence and are designated
“E2C” because two extracellular cysteines 90 and 306 were mutated to alanine,
rendering the E2C hDAT background MTSET-insensitive (Pedersen et al. 2014).
Synthetic cDNA encoding hDAT subcloned into pcDNA3.1+ (provided by Dr.
Haley E Melikian, University of Massachusetts) was used as a template to
generate mutants using site-directed mutagenesis performed by GENEWIZ
(South Plainfield, NJ). DNA sequencing was also performed by GENEWIZ to
confirm the sequences of the mutant constructs. Plasmid DNA were propagated
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and purified using the Qiagen Hi-speed maxi prep plasmid DNA isolation kit
(Qiagen, Valencia, CA, USA).
3.2.3 Cell culture, transfection, and stable cell lines
PC12 cells (ATCC® CRL-1721TM, American Type Culture Collection,
Manassas, VA) were maintained at 37 °C in a 5% CO2 incubator in Dulbecco’s
modified eagle medium (DMEM, Life Technologies, Carlsbad, CA) supplemented
with 15 % horse serum, 2.5 % fetal bovine serum, 2 mM glutamine, and
antibiotics (100 U/ml penicillin and 100 µg/mL streptomycin). HEK293 cells
(ATCC® CRL-1573TM, American Type Culture Collection, Manassas, VA) were
used for the MTSET experiments and were maintained in Eagle’s minimum
essential medium (MEM) supplemented with 10% fetal bovine serum and
antibiotics (100 U/ml penicillin and 100 µg/mL streptomycin). For transient
transfection, cells were seeded into 24-well plates at a density of 1×105
cells/cm2, or allowed to reach 100% confluence, and were transfected 24 h later
with WT hDAT or mutant hDAT plasmid DNA using Lipofectamine 2000 (Life
Technologies, Carlsbad, CA). Cells were used for experiments 24 h after
transfection. In order to generate cell lines stably expressing WT or mutant
hDAT, cells were transfected with Lipofectamine 2000 and cells expressing WT
or mutant hDAT were selected and maintained with G418 (Sigma-Aldrich, St.
Louis, MO).
3.2.4 [3H]DA uptake assay
The maximal velocity (Vmax) and the Michaelis-Menten constant (Km) of
[3H]DA uptake were examined in intact PC12 cells transiently expressing WT or
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mutant hDAT as previously described (Midde et al. 2013). In brief, the cells were
washed twice in 1X Krebs-Ringer-HEPES (1X KRH) buffer, preincubated for 10
min at room temperature with buffer and/or 10 µM nomifensine (final
concentration), and then incubated with the addition of one of six concentrations
of unlabeled DA (final DA concentrations, 0.03-5 µM) and a fixed concentration of
[3H]DA (500,000 DPM/well, specific activity, 21.2 Ci/mmol; PerkinElmer Life and
Analytical Sciences, Boston, MA) at room temperature for 8 min. Specific uptake
was calculated by subtracting nonspecific uptake (in the presence of 10 µM
nomifensine) from total uptake.
The IC50 of DA uptake in WT or mutant hDAT by DAT substrate and
inhibitors was determined in intact PC12 cells seeded into 24-well plates as
reported previously (Quizon et al. 2016). Briefly, cells were preincubated in 1X
KRH buffer containing either DA (1 nM to 1 mM, final concentration), GBR12909
(1 nM to 10 µM, final concentration), cocaine (1 nM to 1 mM, final concentration),
or ZnCl2 (1, 10, 100 μM; final concentration) for 10 min at room temperature and
then incubated for 8 min after the addition of [3H]DA (0.05 µM, final
concentration). The cells were then washed twice with ice-cold 1X KRH buffer.
Cells were lysed in 500 μl of 1% SDS for an hour. Radioactivity was measured
the next day using a liquid scintillation counter (model Tri-Carb 2900TR;
PerkinElmer Life and Analytical Sciences, Waltham, MA). The IC50, Vmax and Km
were determined using Prism 8.0 (GraphPad Software Inc., San Diego, CA).
To determine the effects of Tat inhibition on [3H]DA uptake, cells were
harvested and resuspended in culture medium and allowed to incubate at room
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temperature for 10 min. The detached cells were then pelleted by centrifugation
at 400 × g for 5 min at 4 °C, washed once and resuspended with phosphatebuffered saline, followed by another centrifugation at 400 × g for 5 min at 4 °C,
and finally resuspended in 1X KRH buffer. Specific [3H]DA uptake was
determined in the cell suspensions prepared from WT hDAT and its mutants in
the presence or absence of recombinant Tat1-86 (Diatheva, Fano, Italy; 140 nM,
final concentration). Cell suspensions were preincubated with Tat for 20 min at
room temperature and then incubated for 8 min after adding [3H]DA (0.05 µM,
final concentration). 10 µM nomifensine (final concentration) was used to
determine non-specific [3H]DA uptake. The incubation was terminated by
immediate filtration through Whatman GF/B glass filters (presoaked with 1XKRH
buffer containing 1 mM pyrocatechol for at least 3 h). Filters were washed three
times with 3 ml of ice-cold 1X KRH buffer containing pyrocatechol using a
Brandel cell harvester (model M-48; Brandel Inc., Gaithersburg, MD).
Radioactivity was determined as described above.
To determine whether the H547A-induced increase in Vmax was due to a
palmitoylation-mediated mechanism, [3H]DA uptake kinetic analysis was
performed in the presence or absence of 15 µM 2-BP (2-bromopalmitate or 2bromohexadecanoic acid; MilliporeSigma, St. Louis, MO), a palmitoylation
inhibitor. This concentration was based on previous studies as well as pilot
experiments conducted to determine the optimal concentration (data not shown).
A 1500 µM 2-BP stock was prepared in 100% DMSO and was diluted to 150
µM/10% DMSO working concentration. Intact PC12 cells in 24-well plates
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transiently expressing WT or H547A-hDAT were washed twice with 1X KRH
buffer. To determine the effects of 2-BP exposure at the zero time point (0 h), the
cells were incubated for 8 min at room temperature with 15 µM 2-BP or DMSO
control (veh) and six concentrations of mixed unlabeled and labeled [3H]DA as
described above. 10 µM nomifensine was added to selected wells to determine
nonspecific uptake. To determine specific uptake, nonspecific uptake was
subtracted from total uptake. To determine the effects of 2-BP exposure at the 2
h time point, the cells were incubated similarly as above, but allowed to incubate
at room temperature for 2 h. After each incubation, cells were washed twice with
ice-cold 1X KRH buffer to terminate the reaction, lysed with 500 µl 1% SDS, and
allowed to shake at room temperature for an hour. Lysates were collected into
scintillation vials and radioactivity was measured via liquid scintillation as above.
The Vmax and Km were determined using GraphPad Prism 8.0 (GraphPad
Software Inc., San Diego, CA).
3.2.5 [3H]WIN35,428 Binding Assay
Binding assays were conducted to determine whether mutated hDAT
alters the kinetic parameters (Bmax or Kd) of [3H]WIN35,428 binding in intact PC12
cells transfected with WT hDAT or mutants. Cells were washed with sucrosephosphate buffer (final concentration in mM: 2.1 NaH2PO4, 7.3 Na2HPO47H2O,
and 320 sucrose, pH 7.4) and then incubated with one of the six concentrations
of [3H]WIN35,428 (84 Ci/mmol, PerkinElmer, 0.5 – 30 nM final concentrations) in
a final volume of 500 μl on ice for 2 h. In parallel, nonspecific binding at each
concentration of [3H]WIN35,428 (in the presence of 30 µM cocaine, final
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concentration) was subtracted from total binding to calculate the specific binding.
For the competitive inhibition experiment, assays were performed in duplicate in
a final volume of 500 μl. Intact cells transfected with WT hDAT or its mutants
were incubated in buffer containing 50 μl of [3H]WIN35,428 (final concentration, 5
nM) and one of seven concentrations of unlabeled substrate DA (1 nM – 100
μM), cocaine (1 nM – 100 μM), GBR12909 (0.01 nM – 1 μM) or ZnCI2 (1, 10, 100
μM) on ice for 2 h. Assays were terminated by removal of reaction reagents in
well and then washed three times with ice-cold assay buffer. Cells were lysed
with 1% SDS for an hour. Radioactivity was determined as described above.
3.2.6 Cell surface Biotinylation
To determine whether the mutations alter DAT cell surface expression,
biotinylation assays were performed as described previously (Midde et al. 2015).
PC12 cells transiently expressing WT hDAT or mutants were grown to 90%
confluence in 6-well plates (at a density of 1×105 cells/cm2). Cells were incubated
with 1 ml of 1.5 mg/ml sulfo-NHS-SS biotin (Pierce, Rockford, IL) in PBS/Ca/Mg
buffer (in mM: 138 NaCl, 2.7 KCl, 1.5 KH2PO4, 9.6 Na2HPO4, 1 MgCl2, 0.1
CaCl2, pH 7.3). After incubation, cells were washed 3 times with 1 ml of ice-cold
100 mM glycine in PBS/Ca/Mg buffer and incubated for 30 min at 4°C in 100 mM
glycine in PBS/Ca/Mg buffer. Cells were then washed 3 times with 1 ml of icecold PBS/Ca/Mg buffer and then lysed with 500 ml of Lysis buffer (Triton X-100,
1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM pepstatin, 250 µM phenylmethysulfonyl
fluoride), followed by incubation and continuous shaking for 30 min at 4 °C. Cells
were transferred to 1.5 ml tubes and centrifuged at 17,000 × g for 30 min at 4 °C.
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The resulting pellets were discarded, and 200 µl of the supernatants was stored
at -20 °C as the total DAT fraction. The remaining supernatants were incubated
with continuous shaking with ImmunoPure Immobilized Streptavidin beads in
lysis buffer for 1 h at room temperature. Samples were centrifuged subsequently
at 17,000 × g for 4 min at 4°C, and supernatants (containing the non-biotinylated,
intracellular protein fraction) were stored at -20°C. Resulting pellets containing
the

avidin-absorbed

biotinylated

proteins

(cell

surface

fraction)

were

resuspended in 1 ml of 1.0% Triton X-100 buffer and centrifuged at 17,000 × g
for 4 min at 4°C, and pellets were resuspended and centrifuged twice. Final
pellets consisted of the biotinylated proteins adsorbed to monomeric avidin
beads. Biotinylated proteins were eluted by incubating with 75 µl of Laemmli
sample buffer for 20 min at room temperature and stored at -20 °C until western
blot analysis was conducted.
3.2.7 Basal and MPP+ efflux assay
Basal DA and MPP+ efflux was performed at room temperature as
described previously (Midde et al. 2015). Intact PC12 cells transfected with WT
hDAT or its mutants were preloaded with 0.05 μM [3H]DA for 20 min and then
washed 3 times with KRH buffer prior to collecting fractional efflux samples. To
obtain an estimate of the total amount of [3H]DA or [3H]MPP+ in the cells at the
zero time point, cells from a set of wells (four wells/sample) were lysed rapidly in
1% SDS after preloading with [3H]DA or [3H]MPP+. To collect fractional efflux
samples, buffer (500 μl) was added into a separate set of cell wells and
transferred to scintillation vials after 1 min as an initial fractional efflux, and
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another 500 μl buffer was added to the same wells and collected after 10 min as
second fractional efflux. Additional fractional efflux at 20, 30, 40, 50 min,
respectively, was repeated under the same procedure. After the last fractional
efflux, cells were lysed and counted as total amount of [3H]DA or [3H]MPP+
remaining in the cells from each well.
3.2.8 MTSET assay
This assay was based on the work of Loland and colleagues (Loland et al.
2004, 2008; Pedersen et al. 2014), with a few modifications. First, a cysteineinsensitive background construct was generated based on WT hDAT, E2C, in
which two external endogenous cysteines were mutated into alanines
(C90A/C306A-hDAT or E2C-hDAT). This will reduce background MTSET activity
and serve as the negative control. Then, a cysteine in position 159 was inserted,
resulting in the second construct, C90A/C306A/I159C-hDAT or E2C/I159ChDAT, which is the baseline upon which other mutant constructs with I159C will
be compared. HEK293 cells were seeded onto 24-well plates at a density of
1×105 cells/cm2 or allowed to reach confluence before transfection with WT, the
E2C hDAT background construct, or subsequent E2C mutants. The next day,
intact cells were washed twice with 1X KRH buffer, and preincubated with or
without the presence of 10 µM nomifensine (for non-specific uptake) and 1 mM
MTSET chloride ([2-trimethylammonium)ethyl]-methanethiosulfate) (Santa Cruz
Biotechnology, Dallas, TX) for 10 min at room temperature. While previous
publications reported using 0.5 mM

MTSET for 10 min exhibiting a 40%

inhibition on E2C-I159C (Loland et al. 2004, 2008), 1mM MTSET was used due
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to its ability to induce greater inhibition compared to the 0.5 mM concentration.
Because MTSET is easily hydrolyzed in solution, the amount needed for a 10X
stock was weighed out and dissolved in 1X KRH buffer just moments before
adding to the assigned wells, for a 10-fold dilution (final concentration of 1 mM
and final volume of 250 μl). After preincubation, [3H]DA (0.05 µM, final
concentration) was added and cells were incubated for 8 min at room
temperature. Cells were immediately washed twice with ice-cold 1X KRH buffer
to terminate the incubation and were lysed rapidly with the addition of 1% SDS.
Cell lysates were collected after incubation for 1 h at room temperature and
radioactivity was determined the next day.
3.2.9 Data analysis
Data are presented as means ± SEM, and n corresponds to the number of
independent experiments performed for each group. GraphPad Prism version 8.0
was used to calculate kinetic parameters (Vmax, Km, Bmax, and Kd) from saturation
curves using nonlinear regression via a Michaelis-Menten fit. IC50 values for
substrate and inhibitors inhibiting [3H]DA uptake or [3H]WIN35,428 binding were
determined from a inhibitory curve using a one-site model with variable slope.
For data involving comparisons between unpaired samples, the unpaired
Student’s t test was used to assess differences in kinetic parameters (V max, Km,
Bmax, Kd or IC50) between WT and mutant; log-transformed values of IC50, Km or
Kd were used for the statistical comparisons. To determine significant differences
between samples, data were analyzed with Student’s t tests or separate
ANOVAs followed by post-hoc tests, as indicated in the results and figure
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legends of each experiment. All statistical analyses were performed using IBM
SPSS Statistics version 24, with a significance threshold of p<0.05.
3.3 RESULTS
3.3.1 Computational modeling: Mutations on DAT and Tat attenuate Tat-DAT
interaction
Based on the constructed outward-open hDAT-Tat complex structure
previously reported (Midde et al. 2015; Yuan et al. 2015, 2016a), it has been
found that key molecular interactions between Tat and hDAT include a hydroxyl
group of the Y88 side chain on DAT forming a hydrogen bond with K19 on Tat
(Midde et al. 2015), and the side chain and backbone of H547 on DAT forming a
hydrogen bond with R49 on Tat (Yuan et al. 2016b; Quizon et al. 2016). Single
mutations on these residues (Y88F and H547A) resulted in the significant
disruption of the binding between Tat and DAT (Midde et al. 2015; Yuan et al.
2016b; Quizon et al. 2016). Using the same computational model, it has been
determined that the negatively charged side chain of D206 in DAT forms a
hydrogen bond with the positively charged side chain of R57 in Tat (Figure 3.1A,
3.1B). Therefore, the mutation of these residues (D206L or D381L) in DAT is
expected to impair the hydrogen bond between DAT and Tat (Figure 3.1) and
attenuate the inhibitory effect of Tat on DAT activity. Furthermore, this
computational model has revealed that D206 is a solvent exposed residue in the
extracellular side of the hDAT structure, which resides far away from the
dopamine binding site on the transporter (Figure 3.1). Therefore, D206L is
unlikely to directly interfere with the binding of dopamine with DAT, making this
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residue an ideal target for interfering with Tat-DAT binding without significant
disruption to transporter function. On the other hand, this computational model
reveals that DAT residues Y88, D206, and H547 independently interact with Tat
(Figure 3.1B). This suggests that the combination of these mutants into double
and triple mutant constructs may additively result in greater interference to TatDAT binding. As shown in Figure 3.1C, two hydrogen bonds between Tat and
DAT were eliminated by the double mutation D206L/H547A, while Figure 3.1D
shows that three hydrogen bonds were eliminated by the triple mutation
Y88F/D206L/H547A.
3.3.2 Tat mutant K19A disrupts Tat-DAT interaction
It has been previously reported that key recognition residue Y88 on DAT
directly interacts with residue K19 on Tat and that the mutation Y88F
successfully disrupts the Tat-induced inhibition of DA transport in vitro (Midde et
al., 2015; Yuan et al., 2015; Yuan, Huang, et al., 2016). The current study tested
whether a mutation on Tat protein, K19A, would result in a similar disruption of
Tat-DAT interaction by performing co-immunoprecipitation on mouse striatal
synaptosomes as well as DA uptake and WIN35,428 binding experiments on
PC12 cells transiently expressing WT hDAT. The mutant C22G was used as a
negative control because any mutation on the cysteine-rich domain of
recombinant Tat protein results in loss of functionality (Bertrand, Aksenova,
Mactutus, & Booze, 2013; Midde et al., 2013). In the current study, wild-type and
mutant forms of recombinant Tat1-86 bound to Tat antibody was able to
immunoprecipitate hDAT in varying degrees as shown in Figure 3.2A. C22G
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completely disrupted the interaction while K19A showed decreased density
compared to the wild-type recombinant Tat1-86 (rTat1-86). To determine whether
the K19A mutation on Tat disrupted [3H]DA uptake and [3H]WIN35,428 binding in
PC12 cells expressing WT hDAT, [3H]DA uptake and [3H]WIN35,428 binding
assays were conducted in the presence of 140 nM WT, K19A, or heated rTat1-86.
The addition of WT rTat1-86 resulted in a 40.0% decrease in [3H]DA uptake (59.97
± 4.30%, t(6)=4.34, p<0.01) and a 25.6% decrease in [3H]WIN35,428 binding
(76.20 ± 2.06%, t(6)=4.16, p<0.01) compared to untreated control. The WT Tatinduced decrease in [3H]DA uptake and [3H]WIN35,428 binding was attenuated
by both K19A mutant and heated Tat (ps>0.05). This demonstrates that the K19A
mutant on Tat successfully disrupts Tat-DAT interaction.
3.3.3 Mutants on DAT differentially alter DA uptake kinetics and DAT binding
To determine whether the mutations on hDAT at Asp206 and Asp381
influence DAT function, kinetic analysis of [3H]DA uptake was performed on
PC12 cells transiently transfected with WT hDAT, D206L, or D381L. As shown in
Table 3.1 and Figure 3.3A, compared to WT hDAT (12.43 ± 2.50 pmol/min/10 5
cells), the maximal velocity (Vmax) values were decreased by 63% in D381L (4.54
± 0.95, t(8) = 2.95, p<0.05), while D206L did not alter the Vmax . Both mutants did
not alter Km values. In a separate study, the additive effects of D206L/H547A and
Y88F/D206L/H547A on DAT function was determined. As shown in Table 3.3
and Figure 3.3B, compared to WT hDAT (26.62 ± 3.87 pmol/min/10 5 cells), the
Vmax values were increased by 57% in D206L/H547A (41.82 ± 2.96 pmol/min/10 5
cells, t(6) = 3.12, p<0.05) and decreased by 60% in Y88F/D206L/H547A (10.78 ±
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0.98 pmol/min/105 cells, t(6) = 3.97, p<0.01) respectively. Compared to WT hDAT
(0.45 ± 0.21 µM), Km value in Y88F/D206L/H547A was increased by 324% (1.92
± 0.37 µM, t(6) = 3.44, p< 0.05) but not altered in D206L/H547A.
In the hDAT, [3H]WIN35,428 binding sites share pharmacological identity
with the DA uptake carrier and is part of the cocaine binding domain (Coffey and
Reith 1994; Pristupa et al. 1994). It was then determined whether single point or
multiple mutations of hDAT alter DA binding sites. As shown in Table 3.2 and
Figure 3.4, compared to WT hDAT (3.23 ± 0.58 pmol/10 5 cells), the maximal
binding sites (Bmax) of [3H]WIN35,428 were not altered in D206L and D381L
(ps>0.05); however, the Kd values of D381L significantly increased (17.52 ± 6.57
nM, t(16) = 2.50, p< 0.05) in comparison to WT hDAT (5.98 ± 0.73 nM). As shown
in Figure 3.4, although the Bmax values of [3H]WIN35,428 were not altered in
D206L/H547A and Y88F/D206L/H547A relative to WT hDAT, the K d was
significantly decreased in Y88F/D206L/H547A (6.90 ± 1.26 nM, t(6) = 2.49, p<
0.05) in comparison to WT hDAT (12.53 ± 1.88 pmol/min/10 5 cells).
To determine whether single or multiple mutations on hDAT alter the
subcellular distribution of DAT, biotinylation and subsequent immunoblot assays
were performed in both total and cell surface (biotinylated) fractions from PC12
cells transiently transfected with either WT hDAT or mutants (Figure 3.3C and
3.3D). Compared to WT hDAT, D206L did not alter total and cell surface DAT
expression, which corresponds to the unaltered V max values as shown in Figure
3.3A. Biotinylation was also performed on D381L (Figure 3.3C). Compared to
their respective controls (100%), total DAT and surface DAT were decreased by
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48.4 % [t(8)=3.04, p<0.05] and 40.9 % [t(8)=3.44, p<0.05], respectively, which
correspond to the decreased Vmax compared to WT hDAT (Table 3.1 and Figure
3.3A). Interestingly, although the increased Vmax was observed in D206L/H547A,
this mutant did not alter total and surface DAT relative to WT hDAT. The DAT
expression in Y88F/ D206L/H547A was significantly decreased by 58.4 % in total
[t(6) = 2.76, p< 0.05] and 72.5 % in surface [t(8) = 4.38, p< 0.05] fractions,
respectively, compared to WT hDAT (100%, Figure 3.3D), which corresponds to
the significant decrease in Vmax (Figure 3.3B and Table 3.3).
3.3.4 DAT mutants alter the inhibition potency of DA uptake and DAT binding by
substrates and inhibitors
The ability of DAT substrates (DA) and inhibitors (cocaine and its analog
GBR12909) to inhibit [3H]DA uptake (Table 3.1) was performed in PC12 cells
transiently transfected with WT hDAT, D206L, and D381L. Compared to WT
hDAT (1810 ± 490 nM), D381L exhibited a decrease in IC 50 for DA (340 ± 40 nM,
t(11)=2.70, p<0.05, unpaired Student’s t test), while D206L did not alter the IC50
value. In addition, both D206L and D381L did not alter the IC50 values for cocaine
and GBR12909 relative to WT hDAT. In separate experiments, we determined
the IC50 values of [3H]WIN35,428 binding for DA, cocaine, and GBR12909 in WT
hDAT and mutants. As shown in Table 3.2, both D206L and D381L did not alter
the IC50 values for DA; however, D381L decreased the IC 50 values for cocaine
(1480 ± 276, t(8)=5.70, p<0.001, unpaired Student’s t test) and GBR12909 (2620
± 404, t(8)=3.50, p<0.01, unpaired Student’s t test) compared to WT hDAT (308 ±
55 and 770 ± 193, respectively). Compared to WT hDAT, D206L/H547A
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preserved potencies for DA, cocaine, or GBR12909 for inhibiting [ 3H]DA uptake
(Table 3.3), while Y88F/D206L/H547A increased IC 50 values for DA (1830 ± 587,
t(9)=2.53,

p<0.05, unpaired Student’s t test) and decreased IC50 values for

GBR12909 (180 ± 18, t(8)=5.58, p<0.001, unpaired Student’s t test) compared to
WT hDAT (467 ± 85 and 660 ± 84 nM, respectively). Both double and triple
mutants did not alter the IC50 values for cocaine.
3.3.5 D206L, D206L/H547A, and Y88F/D206L/H547A attenuate Tat-induced
Inhibition of DA Transport
The computational model predicted that altering either Asp206 or Asp381
to Leucine, as well as the combination of mutants Y88F, D206L, and H547A
would interfere with the hydrogen bonds between Tat and DAT (Figure 3.1),
thereby affecting Tat-induced inhibition of DA transport. It has also been
previously confirmed that mutants Y88F and H547A attenuate the inhibitory
effects of Tat on DA uptake (Midde et al. 2015; Yuan et al. 2016b; Quizon et al.
2016). In order to validate the computational predictions experimentally, the
specific [3H]DA uptake and [3H]WIN35,428 binding was measured in the
presence or absence of 140 nM recombinant Tat1-86 in PC12 cells transiently
expressing WT hDAT and mutants. As shown in Figure 3.5A, two-way ANOVA
analysis showed that a significant main effect of treatment (F (1,

18)

= 7.44;

p<0.05); however, no main effects of genotype and interaction were found. Posthoc analysis showed that the addition of Tat significantly decreased DA uptake
by 28.5% in WT hDAT (71.5 ± 3.3 %, F(1, 6) = 19.2; p<0.01) and by 43% in D381L
(68.0 ± 8.9%, F(1, 6) = 9.80, p<0.05), while Tat did not alter DA uptake in D206L
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relative to WT hDAT. In Figure 3.5B, two-way ANOVA analysis showed that a
significant main effect of genotype (F(2,

18)

= 13.0; p<0.001) and interaction of

genotype x treatment (F(2, 18) = 13.0; p<0.001). Post-hoc analysis showed that the
addition of Tat significantly decreased DA uptake by 40.3% in WT hDAT (59.97 ±
4.30%, F(1,

6)

= 18.9, p<0.001), which was attenuated by D206L/H547A and

Y88F/D206L/H547A. As shown in Figure 3.5C, two-way ANOVA analysis
showed no significant main effect of genotype/treatment and their and
interaction; however, Tat significantly decreased DA uptake by 25.6% in WT
hDAT (74.4 ± 2.59%, F(1, 6) = 17.3, p<0.01).
3.3.6 Effects of Mutants on zinc-induced DAT conformational transition and basal
DAT-mediated efflux
WT hDAT contains endogenous zinc (Zn2+) binding sites that serve to
stabilize the transporter in the outward-facing conformation when bound to Zn2+.
This promotes DA binding (thereby increasing [3H]WIN35,428 binding) while
inhibiting DA translocation (decreasing [3H]DA uptake) (Norregaard et al. 1998;
Loland et al. 2003). The addition of Zn2+ partially reverses the transporter from
the inward-facing state to the outward-facing state, making this technique useful
for determining alterations to the transporter’s conformational equilibrium. As
shown in Figure 3.6A, the addition of Zn2+ to WT hDAT resulted in a
concentration-dependent decrease in [3H]DA uptake, with 10 and 100 µM Zn2+
resulting in a 26.93%, and 37.58% decrease in [3H]DA uptake, respectively. A
similar concentration-dependent effect was observed in both D206L (10 µM Zn 2+:
23.53% decrease, 100 µM Zn2+: 35.11% decrease) and D381L (10 µM Zn 2+:
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23.86% decrease, 100 µM Zn2+: 33.79% decrease) as well. Two-way ANOVA
analysis on WT, D381L, and D206L revealed a significant main effect of zinc
concentration (F(3,45)=66.0, p<0.0001) and zinc concentration × mutation
interaction (F(6,45)=9.23, p<0.0001). In Figure 3.6B, the addition of Zn2+ to WT
hDAT resulted in a dose-dependent increase in [3H]WIN35,428 binding, with 10
and 100 µM Zn2+ resulting in a 80.9%, and 82.9% increase in [3H]WIN35,428
binding, respectively. A similar effect was observed in both D381L and D206L
mutants. Two-way ANOVA analysis on WT, D381L, and D206L revealed a
significant main effect of zinc concentration (F(3,33)=39.63, p<0.0001) and zinc
concentration × mutation interaction (F(6,33)=6.68, p<0.0001). In Figure 3.6C, the
addition of Zn2+ to WT hDAT resulted in a dose-dependent decrease in [3H]DA
uptake, with 10 and 100 µM Zn2+ resulting in a 55.8%, and 68.2% decrease in
[3H]DA uptake, respectively. A similar dose-dependent effect was observed in
both D206L/H547A (10 µM Zn2+: 70.35% decrease, 100 µM Zn2+: 84.4%
decrease) and Y88F/D206L/H547A (10 µM Zn2+: 63.73% decrease, 100 µM Zn2+:
88.77% decrease), as well. Two-way ANOVA analysis on WT, D206L/H547A,
and Y88F/D206L/H547A specific [3H]DA uptake revealed a significant main effect
of zinc concentration (F(3,27)=92.61, p<0.0001) and zinc concentration × mutation
interaction (F(6,27)=21.89, p<0.0001). On the other hand, Figure 3.6D shows that
the addition of Zn2+ to WT hDAT resulted in a dose-dependent increase in
[3H]WIN35,428 binding, with 10 and 100 µM Zn 2+ resulting in a 39.2%, and
52.0% increase in [3H]WIN35,428 binding, respectively. However, D206L/H547A
and Y88F/D206L/H547A attenuated the Zn 2+-induced increase in [3H]WIN35,428
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binding (Figure 3.6D). Two-way ANOVA analysis on [3H]WIN35,428 binding in
WT, D206L/H547A, and Y88F/D206L/H547A revealed a significant main effect of
zinc concentration × mutation interaction only (F (6,36)=2.99, p<0.05), suggestive of
altered binding sites in both mutants.
To

further

examine

whether

the

mutants

altered

transporter

conformational transitions, basal efflux of DA and MPP+ was examined and found
no significant differences between WT hDAT and mutants D206L or D381L
(Figure 3.7A, 3.7B, and 3.7C). As shown in Figure 3.7D, compared to WT,
D206L/H547A had a higher overall MPP+ efflux activity. Two-way ANOVA
analysis reveals a main effect of genotype (F(2,126)=29.04, p<0.001) and time
(F(5,126)=10.17, p<0.001). No significant interaction of genotype × time was found
(F(10,126)=1.78, p = 0.072). Post hoc analyses showed that compared to WT
hDAT, the MPP+ efflux levels were elevated at 1 and 10 min in D206L/H547A
(p<0.05, Bonferroni t-test). This suggests that the double mutant D206L/H547A
may have altered transporter conformational transitions.
3.3.7 H547A mutant renders the transporter into a more outward-facing
conformation and alters basal palmitoylation
It is interesting to note that the Vmax was not altered in D206L but
increased in H547A (Quizon et al. 2016), suggesting that the H547A mutant
plays a critical role in D206L/H547A-increased DA uptake. To determine whether
the increased DA uptake exhibited by H547A is due to transporter conformational
alterations, a functional assay called the substituted cysteine accessibility
method was utilized. This assay is specific for the measurement of the reactivity
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of a mutation of hDAT at I159 (isoleucine to cysteine, I159C) to MTSET ([2(trimethylammonium) ethyl] methane thiosulfonate), which inhibits DA uptake by
impeding DA translocation (Loland et al. 2004). As shown in Figure 3.8A, a pilot
study was designed to determine the optimal MTSET concentration that
significantly decreases DA uptake in MTSET-sensitive E2C-I159C construct,
while the MTSET-insensitive E2C-hDAT construct remains unchanged. The
addition of MTSET to E2C-I159C produced a 36.96% and 55.10% decrease in
DA uptake at 0.5 mM and 1.0 mM, respectively, compared to WT hDAT, which is
consistent with previous reports (Loland et al. 2004, 2008). Based on the pilot
study, the effects of MTSET on the combination of E2C/H547A, E2CI159C/H547A or E2C-I159A/H547A was further determined (Figure 3.8B).
Compared to their respective controls (100%), the addition of MTSET did not
affect DA transport in E2C and E2C/H547A; however, DA uptake was decreased
by 54.02 % in E2C-I159C (t(8) = 6.34, p<0.001), 69.60 % in E2C-I159C/H547A
(t(8) = 5.24, p<0.001), and 41.46% in E2C-I159A/H547A (t(8) = 2.14, p<0.05).
Comparing the difference among the MTSET-treated groups, two-way ANOVA
analysis reveals significant main effects of genotype (F(4,40)=139.67, p<0.001)
and treatment (F(1,40)=40.03, p<0.001), and genotype × treatment interaction
(F(4,40)=2.62, p<0.05).

Post hoc analyses with single comparison show that

compared to E2C, DA uptake was significantly decreased by 37.25% in E2CI159C (t(8) = 4.66, p<0.001). The combination of E2C-I159C with H547A further
resulted a 17.57% reduction of DA uptake in E2C-I159C/H547A (t(8) = 2.17,
p<0.05), suggesting that the outward-open state in H547A produces greater
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accessibility to the engineered MTSET binding site, I159C. Interestingly, the
elimination of MTSET-sensitive binding in E2C-I159A/H547A (33 ± 4.1%)
reversed the E2C-I159C-induced decrease in DA uptake relative to E2CI159C/H547A (58.54 ± 7.7, t(8) = 2.92, p<0.05). Greater DA uptake inhibition in
the presence of MTSET suggests that the H547A mutant causes the transporter
to favor a more outward-facing conformation, which may explain its dramatic
increase (196%) in DA uptake.
It has been previously demonstrated that the H547A-induced increase in
Vmax is mediated by alterations in basal PKC activity (Quizon et al. 2016). Recent
studies reported that DAT kinetics is also regulated by a reciprocal
phosphorylation

and

palmitoylation

mechanism,

where

increased

phosphorylation results in decreased DAT V max and palmitoylation, and viceversa (Moritz et al. 2015; Rastedt et al. 2016; Foster and Vaughan 2017). To
determine whether the H547A-induced increase in DA uptake is a result of
alteration of basal palmitoylation levels, the Vmax of DA uptake in WT hDAT and
H547A was determined in the presence or absence of palmitoylation inhibitor 2BP (2-bromopalmitate). As shown in Figure 3.8C and 3.8D, a pilot study was
designed to determine the time-dependent inhibitory effect of 2-BP on DA
uptake. At the zero time point, 2-BP had no inhibitory effect on DA uptake in WT
hDAT and H547A (Figure 3.8C). At two-hour point, two-way ANOVA reveals a
significant main effect of treatment (F(1,5)=81.71, p<0.001) and a trend
significance of genotype × treatment (F(1,5)=5.88, p=0.06). Post hoc analysis
shows that compared to their respective controls, 2-BP significantly produced a
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38% decrease in WT hDAT (t(6) = 3.45, p<0.05) and 62% in H547A (t(6) = 2.97,
p<0.05). Compared to WT hDAT, 2-BP further produced a 25% decrease in DA
uptake in H547A (t(6) = 2.60, p<0.05). This suggests that H547A alters basal
palmitoylation, resulting in enhanced DA uptake. Taken together, these results
suggest that the “DA enhancer” effect observed in H547A may be a result of both
conformational alterations as well as changes in basal phosphorylation and
palmitoylation.
3.4 DISCUSSION
The current study evaluated the effects of single (D206L, D381L), double
(D206L/H547A), and triple (Y88F/D206L/H547A) mutants on basal DA uptake,
Tat-induced inhibition of DA uptake, and transporter conformational transitions.
These studies also evaluated whether a mutation on Tat protein would disrupt
Tat-DAT interaction. First, introducing a mutation on recombinant Tat 1-86 at
position 19 (K19A, which directly interacts with Y88 on hDAT) resulted in the
attenuation of Tat-induced inhibition of DA uptake in WT hDAT. A second major
finding reveals that D206L and D206L/H547A preserved normal DA uptake, while
D381L and Y88F/D206L/H547A resulted in decreased DA uptake activity. The
inhibitory effect of Tat on DA uptake and binding as observed in WT hDAT was
attenuated by D206L, D206L/H547A, and Y88F/D206L/H547A. It was also
confirmed that the dramatic increase in DA uptake that was observed in H547A
(Quizon et al. 2016) is due to the transporter’s shift to a more outward-facing
conformation, as well as a palmitoylation-dependent mechanism that increases
DAT Vmax. Taken together, these results provide mechanistic insights into
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identifying targets on DAT for Tat binding which may aid in drug discovery efforts
for correcting dysfunctional dopaminergic neurotransmission in patients afflicted
with HAND.
Ideally, the mutant constructs should preserve normal DA uptake while
impeding Tat-DAT binding by counteracting the inhibitory effects of Tat on DA
uptake. The computational model of hDAT and the Tat-DAT complex reveals that
D-D206 and D-D381 of hDAT match these ideal characteristics (the prefix Tindicates Tat and D- indicates DAT hereafter). First, D-D206 and D-D381 are
solvent exposed, which indicates that they are not involved in direct interaction
with other parts of hDAT. Therefore, this model predicts that mutating these two
residues may not disturb the hDAT transport process. Second, residues D-D206
and D-D381 are far away from the dopamine binding site, which indicates that
the mutation of these two residues is not likely to influence substrate (i.e.,
dopamine) binding. Third, residues D-D206 and D-D381 of hDAT form two
hydrogen bonds with T-R56 and one hydrogen bond with T-R57 of Tat,
respectively, which indicates that the mutation of D-D206 and D-D381 are
capable of interfering with hDAT and Tat binding. On the other hand, residues DH547, D-D206, and D-Y88 could form hydrogen bonds with T-R49, T-R57, and
T-K19, respectively. According to previously published computational and
experimental validation data, the single hDAT mutants H547A, D206L, or Y88F
could significantly attenuate the binding between DAT and Tat. It could be
observed that D-H547, D-D206, and D-Y88 independently interact with Tat
(Figure 3.1A, 3.1B), which suggests the possible additive effect of the double or
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triple mutation on impeding Tat-DAT binding. Two hydrogen bonds in the TatDAT interface were eliminated by double mutation D206L/H547A on hDAT (Fig.
3.1C), and three hydrogen bonds in the Tat-DAT interface were eliminated by
triple mutation Y88F/D206L/H547A on hDAT (Figure 3.1D). Therefore, it could be
expected

that

double

mutation

D206L/H547A

and

triple

mutation

Y88F/D206L/H547A would be more effective in inhibiting Tat-DAT binding than
single mutation H547A, D206L, or Y88F. Results of [3H]DA uptake assays for
mutant D206L, D381L, D206L/H547A, and Y88F/D206L/H547A show that: (1)
except for Y88F/D206L/H547A, these mutations do not significantly alter the K m
of dopamine uptake (Table 3.1 and Table 3.3); (2) both D206L and
D206L/H547A

preserve

normal

hDAT

function,

while

D381L

and

Y88F/D206L/H547A decrease the Vmax of dopamine uptake (Table 3.1 and Table
3.3); (3) all tested mutants, except for D381L, attenuate the Tat-induced inhibition
of DA uptake (Figure 3.5). Out of all the mutants, only D381L did not match the
computational predictions via the pharmacological validation studies. This may
be explained by the fact that compared to D206L which is capable of binding to
both T-R56 (with two hydrogen bonds at 2.1 Å and 2.2 Å distance) and T-R57
(with one hydrogen bond at 2.0 Å) of Tat, D381L has been only observed to bind
to T-R57, with a relatively larger distance (one hydrogen bond at 2.4 Å, data not
shown). Despite this one discrepancy, these overall results are consistent with
the computational predictions, which confirm the computational model of the TatDAT complex.
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To further validate the Tat-DAT complex model, it was necessary to
confirm whether mutating key recognition binding sites on Tat protein would also
result in the disruption of the interaction between Tat and hDAT. This
computational model has predicted that Y88 of DAT directly interacts with K19 of
Tat,

which

has

been

confirmed

in

the

current

study

through

co-

immunoprecipitation with mouse striatal synaptosomes as well as DA uptake and
WIN35,428 binding studies with PC12 cells expressing WT hDAT. These results
have shown that mutating K19 to an alanine (K19A) is able to disrupt Tat-DAT
binding as evidenced by decreased optical density on the co-immunoprecipitation
experiment as well as the attenuation of the inhibitory effects of wild-type
recombinant Tat1-86 in vitro (Figure 3.2). Although the disruption is not as
profound as mutating C22 of Tat into a glycine (C22G) which causes Tat to lose
all functionality (Zhu et al. 2009; Aksenov et al. 2009; Midde et al. 2012), K19A
exhibits a marked difference compared to WT recombinant Tat1-86.

These

findings support the site-directed mutagenesis studies and further confirm the
computational predictions. Future studies should focus on delving further into Tat
recognition residues and conducting site-directed mutagenesis experiments on
rTat1-86 to support the previous studies on DAT.
The study of multiple mutants has traditionally been utilized to uncover key
mechanistic insights underlying monoamine transporter pharmacokinetics and
function (Penado et al. 1998; Itokawa et al. 2000). Furthermore, because Tat
protein interacts with more than one recognition residue at a time, combined
mutant constructs were generated to evaluate the effects of these key binding
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targets on DAT functionality as well as their ability to attenuate the inhibitory
effects of Tat protein. As mentioned in the previous section, all mutants
attenuated the inhibitory effects of Tat protein on DA uptake and WIN35,428
binding, except for D381L (Figure 3.5). While the single mutants D206L and
D381L preserved and decreased DA uptake respectively, the double mutant
D206L/H547A and triple mutant Y88F/D206L/H547A resulted in a respective
increase and decrease in uptake (Table 3.3, Figure 3.3). In order to evaluate
whether the kinetic differences in uptake and binding were due to alterations in
cell surface expression, biotinylation studies were conducted. Both D206L and
D206L/H547A

preserved

normal

DAT

surface

expression

while

Y88F/D206L/H547A showed a significant decrease (Figure 3.3). Since DAT
surface expression is an indicator of DA uptake efficiency (Zhu and Reith 2008),
these results correspond with the kinetic data from Table 3.3 showing a
decreased Vmax and Km for Y88F/D206L/H547A. It is interesting to note that the
combination of three mutants resulted in a marked decrease in DA uptake,
despite the fact that single mutants Y88F and D206L preserve uptake (Midde et
al. 2015) and H547A dramatically enhances it (Quizon et al. 2016). The current
trend that was observed so far regarding the combinations of key mutants
residues based on the Tat-DAT complex model is that double mutants (e.g.,
Y88F/H547A)

increase

[3H]DA

Vmax

while

triple

mutants

(e.g.,

Y88F/K92M/H547A) show a dramatic decrease (Sun et al. 2019). While most
double and triple mutants in monoamine transporters have been reported to
result in decreased DA uptake (Itokawa et al., 2000; Kitayama et al., 1992;
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Penado et al., 1998), it is interesting to observe that a mutating another key Tat
residue (i.e., Y88F or D206L) alongside H547A has so far resulted in an increase
in DA uptake Vmax, a relatively rare occurrence in published literature. This
suggests that H547 plays a key role in the DA translocation process. Elucidating
the mechanisms underlying enhanced DA uptake Vmax through these mutants will
pave the way for a novel therapeutic target for the treatment of DAT-mediated
dysregulation of dopaminergic function.
The current study has found that combining the D206L mutation with
H547A (D206L/H547A) resulted in an increase in DA uptake which is consistent
with a previously generated double mutant, Y88F/H547A (Sun et al. 2019). This
suggests that H547A plays a critical role in the DA uptake process. In order to
investigate whether DAT undergoes possible conformation changes with the
H547A-hDAT mutant, the substituted cysteine accessibility method (SCAM) was
utilized, an assay that allows the functional evaluation of the transporter’s
conformational state (Torres et al. 2003). Previous reports indicate that the
accessibility of a cysteine inserted into position 159 in DAT (Ile159Cys), the
norepinephrine transporter (NET, Ile155Cys), and serotonin transporter (SERT,
Ile179Cys) is highly dependent on whether the transporter is outward or inward
facing (Chen and Rudnick 2000; Loland et al. 2004). If the extracellular gate is
open (outward-facing), the inserted cysteine (Ile159Cys in DAT) is accessible to
the extracellular environment and inaccessible when the extracellular gate is
closed (Loland et al. 2004). The addition of sulfhydryl-reactive, cell-impermeable,
and

positively-charged

compound

[2-(trimethylammonium)

88

ethyl]methane

thiosulfonate (MTSET) to a transporter construct with the Ile159Cys mutation
inactivates the transporter, resulting in a 60% inhibition of DAT activity, allowing
the use of specific DA uptake as a functional measure for I159C reactivity to
MTSET (Loland et al. 2004, 2008). Using these principles, inserting a cysteine in
position 159 alongside the H547A mutation will allow the evaluation of the
accessibility of this engineered cysteine: greater DA uptake inhibition in the
combined E2C-I159C/H547A mutant indicates greater accessibility of I159C to
the extracellular space, suggesting that the transporter has been rendered to a
more outward-facing conformation, which was demonstrated in Figure 3.8. This
suggests that DA translocation more readily occurs due to a structural change
induced by the H547A mutation, allowing the transporter to exist more favorably
in an outward facing state, which facilitates enhanced DAT uptake. Further
MTSET assays on double mutants D206L/H547A and Y88F/H547A must be
conducted in order to confirm whether a similar conformation change is
responsible for the elevated DA uptake observed in these mutants.
Finally, this study investigated whether the increased DA uptake in H547A
is due to alterations in basal palmitoylation activity. Palmitoylation is a
posttranslational modification wherein a cysteine receives palmitate, a C16saturated palmitic acid, through a thioester linkage (Resh 2006; Foster and
Vaughan 2011). Phosphorylation and palmitoylation in DAT have been found to
work in a reciprocal manner, with an increase in phosphorylation coinciding with
a decrease in palmitoylation (Moritz et al. 2015). Phosphorylation (usually
mediated by PKC) reduces DA uptake through increased DAT endocytic
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trafficking, while palmitoylation has been found to increase DA uptake (Moritz et
al. 2015; Rastedt et al. 2016; Foster and Vaughan 2017). It was previously
reported that there is an increased sensitivity to PMA-induced phosphorylation in
H547A compared to WT hDAT (Quizon et al. 2016). To determine whether this
corresponds to altered basal palmitoylation in H547A, V max values in the
presence or absence of palmitoylation inhibitor, 2-BP, as measured. H547A
displayed a greater sensitivity to 2-BP-induced downregulation of DA uptake
compared to WT hDAT, which suggests that the H547A-induced increase in Vmax
is highly dependent on palmitoylation activity. Future studies should address
whether the increased DA uptake by other H547A double mutants(Y88F/H547A
and D206L/H547A) is due to alterations in basal palmitoylation.
In summary, the functional influence of single hDAT mutants D206L and
D381L

as

well

as

double

and

triple

mutants

D206L/H547A

and

Y88F/D206L/H547A in basal DA transport and Tat-induced inhibition of DA
transport were investigated. Along with functional residues identified from
previous studies, this characterization of the Tat-DAT binding complex will aid in
the development of novel compounds that would block Tat while preserving
normal DAT activity. This study also revealed that H547A enhances DA uptake
through a conformational alteration, opening up the possibilities for creating
therapeutic compounds for correcting disrupted dopaminergic neurotransmission.
Future studies should explore the creation of small molecule compounds that
would interact with these critical recognition binding residues to aid in the
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development of prophylactics for HIV-positive patients in the early stages of
disease.
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Table 3.1. Summary of kinetic properties and inhibitory activities in [ 3H]DA uptake
in WT hDAT and mutants

IC50 (nM)

Vmax
(pmol/min/105
cells)

Km
(µM)

WT hDAT

12.43 ± 2.50

D206L

D381L

DA

Cocaine

GBR12909

1.39 ± 0.36

1810 ± 490

350 ± 60

300 ± 110

13.09 ± 3.55

1.66 ± 0.78

1970 ± 520

570 ± 70

270 ± 70

4.54 ± 0.95*

1.04 ± 0.34

340 ± 40*

560 ± 110

240 ± 60

Data are presented as mean ± S.E.M. values from five to seven independent
experiments performed in duplicate. * p < 0.05, unpaired student’s t test compared to
WT hDAT.
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Table 3.2. Summary of kinetic properties and inhibitory activities in [ 3H]WIN35,428
binding in WT hDAT and mutants

IC50 (nM)

Bmax
(pmol/105
cells)

Kd (µM)

WT
hDAT

3.23 ± 0.58

D206L

D381L

DA

Cocaine

GBR12909

5.98 ± 0.73

1350 ±
382

308 ± 55

770 ± 193

2.87 ± 0.96

6.37 ± 1.42

1882 ±
409

566 ± 116

1618 ± 456

2.00 ± 0.63

17.52 ± 6.57*

670 ± 292

1480 ± 276***

2620 ±
404**

Data are presented as mean ± S.E.M. values from five to seven independent
experiments performed in duplicate. * p < 0.05, ** p < 0.01, *** p < 0.001 unpaired
student’s t test compared to WT hDAT.
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Table 3.3. Summary of kinetic properties and inhibitory activities in [ 3H]DA uptake
in WT hDAT and mutants

IC50 (nM)

Vmax
(pmol/min/105
cells)

Km
(µM)

WT hDAT

26.62 ± 3.86

D206L/H547A

Y88F/D206L/
H547A

DA

Cocaine

GBR12909

0.45 ± 0.21

467 ± 85

152 ± 48

660 ± 84

41.82 ± 2.96*

0.69 ± 0.10

695 ± 37

141 ± 67

477 ± 85

10.78 ± 0.98*

1.92 ± 0.37*

1830 ±
587*

121 ± 30

180 ± 18*

Data are presented as mean ± S.E.M. values from five to seven independent
experiments performed in duplicate. * p < 0.05, unpaired student’s t test compared to
WT hDAT.
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(A)
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TAT
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T-R57
T-K19

DAT
D-Y88
T-R49

(C)

(D)

D-D206L

D-H547

D-D206L
T-R57

T-R57

T-K19

T-K19

D-Y88F

D-Y88
T-R49

T-R49

D-H547A

D-H547A

Figure 3.1 Key residues D-H547, D-Y88 and D-D206 involved in the HIV-1 Tat-DAT
binding. (A) Typical Tat-DAT binding complex from MD trajectory. Tat and DAT are
represented as gold and cyan ribbons, respectively. The dashed box indicates the
binding surface between Tat and DAT. (B) Residues T-K19, T-R49 and T-R57 of HIV-1
Tat are represented as ball-stick style and colored in yellow. Residues D-H547, D-Y88
and D-D206 are represented as ball-stick style and colored in green. Dashed lines
represent inter-molecular hydrogen bonds with labeled distances. (The prefix T- and Dindicates residues of Tat and DAT, respectively). (C) Double mutation D-D206L/DH547A on TAT-hDAT structure. D-H547A mutation eliminates one hydrogen bond with
T-R49, and D-D206L mutation eliminates the hydrogen bond with T-R57. (D) Double
mutation D-Y88F/D-D206L/D-H547A on TAT-hDAT structure. Addition to the mutational
effects of D-Y88F, D-D206L, and D-H547A also eliminate the hydrogen bond with TK19.
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Figure 3.2 Disruption of the direct interaction between Tat and DAT by mutated Tat1-86.
(A) Co-IP of wild-type recombinant Tat1-86 (rTat1-86) and its mutants with DAT was
performed by immunoprecipitation (IP) with anti-DAT antibody as a bait and immunoblot
(IB) with anti-Tat antibody. Mouse striatal synaptosomes were preincubated with rTat1-86
(+, lane 2 from left) and Tat mutants (C22G, K19A, lane 3 and 4 from left) or without (-,
lane 1 from left). Wild-type rTat1-86 bound to agarose beads was able to
immunoprecipitate DAT (lane 2), which was diminished in C22G and K19A mutants. (B)
Mutation of rTat1-86 at Cys22 or Lys19 attenuates Tat-induced inhibition of DA uptake.
PC12 cells transiently transfected with WT hDAT were preincubated with or without 140
nM rTat1-86 and Tat mutants at room temperature for 20 min followed by addition of a
single mixed concentration (5 nM) of [3H]DA. Specific DA uptake was determine in the
presence of 10 µM nomifensine. Heated rTat1-86 was used as a negative control. (C)
Mutation of rTat1-86 at Cys22 or Lys19 attenuates Tat-induced inhibition of DAT binding
site. PC12 cells transiently transfected with WT hDAT were preincubated with 5 nM
[3H]WIN35,428 on ice for 2 h in the presence or absence of 140 nM rTat1-86 and Tat
mutants. Specific [3H]WIN35,428 binding was determine in the presence of 30 µM
cocaine. Heated rTat1-86 was used as a negative control. Data are expressed as means
from four to five independent experiment ± S.E.M. ** p<0.01, compared to control (in the
absence of Tat).
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Figure 3.3 Kinetic analysis of [3H]DA uptake and DAT surface expression in WT hDAT
and mutants. DA uptake was determined in intact PC12 cells expressing WT hDAT
(WT), D206L, D381L (A), D206L/H547A, or Y88F/D206L/H547A (B) using six
concentrations of DA ranging from 0 μM to 5 μM mixed with a fixed concentration of
[3H]DA (500,000 dpm/well, specific activity: 21.2 Ci/mmol) . In parallel, nonspecific
uptake of each concentration of [3H]DA (in the presence of 10 μM nomifensine, final
concentration) was subtracted from total uptake to calculate the specific DAT-mediated
uptake. The Vmax and Km values were calculated by fitting the data to the MichaelisMenten equation and represent the means from four to five independent experiments ±
S.E.M. * p < 0.05 compared to the respective WT hDAT (unpaired Student’s t test). (CD) Biotinylation assays were used to analyze DAT cell surface expression in PC12 cells
expressing WT hDAT or its mutants. Representative immunoblots (see Appendix B for
supplementary data) and quantification are shown as means ± S.E.M (n=4-5). *p<0.05,
**p<0.01 compared to WT.
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Figure 3.4. Saturation binding of [3H]WIN35,428 in intact PC12 cells transfected with WT
hDAT and mutants. PC12 Cells expressing WT hDAT (WT), D206L, or D381L (A) or
WT, D206L/H547A, or Y88F/D206L/H547A (B) were incubated with indicated
concentrations of [3H]WIN35,428 (0.5 – 30 nM) on ice for 2 h while in parallel,
nonspecific wells were incubated with both 30 μM cocaine (final concentration) and
[3H]WIN35,428. The Bmax and Kd values were generated via a nonlinear one-site binding
curve fit and represent the means from four independent experiments (mean ± S.E.M.,
n=4). *p<0.05 compared to WT (unpaired Student’s t test).
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Figure 3.5. Inhibitory effects of Tat on [3H]DA uptake and [3H]WIN35,428 binding in WT
hDAT and mutants. (A-B) PC12 cells expressing WT hDAT (WT) or mutant were
preincubated with or without recombinant Tat 1-86 (rTat1-86, 140 nM, final concentration) at
room temperature for 20 min followed by the addition of [ 3H]DA. In parallel, nonspecific
uptake (in the presence of 10 μM nomifensine, final concentration) was subtracted from
total uptake to calculate DAT-mediated uptake. Data are presented as a percentage of
untreated control per group, expressed as means ± S.E.M (n=3-4). Values in DPM for
WT vs D206L and D381L: WT (control, 825.63 ± 46 vs Tat, 592.63 ± 55.04), D206L
(control, 789.75 ± 163.55 vs Tat, 735.75 ± 177.90), D381L (control, 652.90 ± 90.04 vs
Tat, 433.50 ± 94.74). Values in DPM for WT vs D206L/H547A: WT (control, 1524.88 ±
124.23 vs Tat, 913.00 ± 110.79), D206L/H547A (control, 997.63 ± 123.89 vs Tat, 961.88
± 108.27). (C) PC12 cells expressing WT or mutant were incubated with or without
recombinant Tat1-86 (rTat1-86, 140 nM, final concentration) and [3H]WIN35,428 on ice for 2
h. In parallel, nonspecific binding (in the presence of 30 μM cocaine, final concentration)
was subtracted from total binding to calculate specific binding. Values in DPM: WT
(control, 7118.25 ± 397.41 vs Tat, 5312.50 ± 481.03), D206L/H547A (control, 7978.00 ±
655.94 vs Tat, 8522.00 ± 1115.47). *p< 0.05 compared to the percentage of control (in
the absence of Tat).
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Figure 3.6. Effects of hDAT mutants on transporter conformational transitions. Mutants
D381L and D206L do not affect zinc regulation of [ 3 H]DA uptake (A) and [3H]WIN35,428
binding (B). Double mutant D206L/H547A and triple mutant Y88F/D206L/H547A further
enhanced zinc-induced decrease in DA uptake (C) while attenuating zinc’s effect on WIN
binding (D). PC12 cells transiently expressing WT hDAT (WT) or mutants were
incubated with buffer alone (control) or three concentrations of ZnCl 2 (1, 10, or 100 μM,
final concentration) followed by [3H]DA uptake or [3H]WIN35,428 binding (n = 5-6). The
graphs illustrate specific [3H]DA uptake and [3H]WIN35,428 binding expressed as mean
± S.E.M. of the respective controls set to 100% for mutants. *p < 0.05, ***p < 0.001
compared to control.
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Figure 3.7. Effects of hDAT mutants on functional efflux of basal DA and MPP +.
Functional DA efflux of D206L (A) and D381L (B), and MPP+ efflux of D206L and D381L
(C), and D206L/H547A-hDAT and Y88F/D206L/H547A (D) with their respective WT
hDAT (WT) controls. PC12 cells transfected with WT or mutants were preincubated with
KRH buffer containing [3H]DA (0.05 µM, final concentration) or [3H]MPP+ (0.005 µM, final
concentration) at room temperature for 20 min. After incubation, cells were washed and
incubated with fresh buffer at indicated time points. Subsequently, the buffer was
removed from cells, and radioactivity in the buffer and residual radioactivity in the cells
was counted. Each fractional efflux of [ 3H]DA or [3H]MPP+ in WT or mutants was
expressed as a percentage of total [3H]DA or [3H]MPP+ in the cells at the start of the
experiment. Fractional [3H]DA or [3H]MPP+ efflux levels at 1, 10, 20, 30, 40 and 50 min
are expressed as a percentage of total [3H]DA with preloading with 0.05 µM or total
[3H]MPP+ with preloading with 0.005 µM introduced to the cells at the start of the
experiment (n = 4-5). *p<0.05, **p<0.01 compared to WT (Bonferroni t-test).
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Figure 3.8. H547A renders an inserted cysteine more reactive to MTSET inactivation
and alters basal palmitoylation compared to WT hDAT. HEK293 cells transiently
expressing WT hDAT (WT) or E2C hDAT constructs were treated with a range of
concentrations (0.1, 0.5, 1.0 mM) of MTSET for 10 mins followed by the addition of 5 nM
[3H]DA for 8 mins. (A) the concentration-dependent effects of MTSET on DA uptake
(*p<0.05, ***p<0.001; n=3). (B) Effects of 1 mM MTSET on DA uptake in E2C, E2CI159C, E2C/H547A, E2C-I159C/H547A, and E2C-I159A/H547A (*p<0.05, **p<0.01
compared to the respective controls). #p<0.001, compared to E2C; ×p<0.05 compared
to E2C-I159C; ××p<0.05 compared to E2C-I159C/H547A. (C) Effects of 2-BP on DA
uptake at zero time point in WT hDAT and H547A. Raw V max values at 0h: WT hDAT
(control, 4.57 ± 0.59 vs 2-BP, 5.36 ± 0.74), H547A (control, 5.63 ± 1.24 vs 2-BP, 6.41 ±
1.45). (D) Effects of 2-BP on DA uptake at two-hour time point in WT hDAT and H547A.
*p<0.05 compared to control; #p<0.05 compared to 2-BP treated WT. Raw Vmax values
at 2h: WT hDAT (control, 8.80 ± 0.92 vs 2-BP, 5.55 ± 0.92), H547A (control, 16.33 ±
0.99 vs 2-BP, 5.66 ± 1.93).
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CHAPTER 4

PROOF-OF-CONCEPT STUDIES USING NOVEL ALLOSTERIC
MODULATORS TO ESTABLISH THEIR POTENTIAL FOR
THERAPEUTIC APPLICATION IN HAND 3

3

Quizon, P. M., Wang, YY., Stacy, H. M., Eans, S. O., Patel, P., Zhang, S., Strauss, M. J.,
McLaughlin, J. P., Zhan, CG., Ananthan, S., & Zhu, J. (2019). Proof-of-concept studies using
novel allosteric modulators to establish their potential for therapeutic application in HAND. In
preparation for submission to Scientific Reports.
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ABSTRACT: Cocaine abuse has been shown to increase the incidence of HIV-1
associated neurocognitive disorders. It has been demonstrated that HIV-1 Tat
allosterically modulates dopamine (DA) reuptake via the human DA transporter
(hDAT). This study determined whether a novel allosteric modulator, SRI-32743,
pharmacologically blocks Tat binding to hDAT and alleviates Tat-potentiated
cocaine rewarding effects in inducible HIV-1 Tat transgenic (iTat-tg) mice. SRI32743 inhibited [3H]DA uptake (IC50, 9.9 µM) with a 17-fold greater inhibition than
the potency of [3H]WIN35,428 binding (IC50, 168 µM) with 68.4% and 71.4% of its
Emax, respectively. Tat (140 nM) induced a 28% reduction in [3H]DA uptake which
was attenuated by SRI-32743 and SRI-31596. SRI-32743 alone and SRI-31596
alone did not alter DAT uptake. Both SRI-32743 and indatraline, a competitive
DAT inhibitor, increased the cocaine IC 50 values of [3H]DA uptake by 45% and
172%, respectively. The cocaine (10 µM)-induced dissociation rate (k-1 = 0.147 ±
0.022 min-1) of [3H]WIN35,428 binding was slowed by the addition of 50 nM SRI32743 in combination with cocaine (k-1 = 0.086 ± 0.014 min-1) and by 50 nM SRI32743 alone (k-1 = 0.069 ± 0.010 min-1). Following a 14 day-doxycycline
treatment to induce Tat protein expression, the iTat-tg mice exhibited a 2-fold
potentiation of cocaine-CPP which was dose-dependently ameliorated by
pretreatment of SRI-32743 (1 or 10 mg/kg/day, i.p.) prior to CPP. These results
demonstrate that developing allosteric modulatory molecules which attenuate
cocaine and Tat binding to DAT will aid drug discovery efforts in the search for
therapeutic interventions for HIV-infected patients who are concurrent abusers of
cocaine.
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4.1 INTRODUCTION
The introduction of antiretroviral therapy (ART) in the mid-nineties has
transformed HIV-1 infection from a terminal diagnosis into a manageable chronic
disease. Currently, there is an estimated thirty-seven million people worldwide
living with HIV (UNAIDS 2016). This is a direct consequence of improved access
to ART leading to increased life expectancy and dramatic reduction in HIV- or
AIDS-related deaths (Simioni et al. 2010; Bonnet et al. 2013). Because most
ART cannot efficiently cross the blood-brain barrier (BBB), the brain serves as a
viral reservoir that continues to infect susceptible cells in the brain. As a result,
up to 70% of HIV-1 positive individuals suffer from neurological complications
that are collectively known as HIV-associated neurocognitive disorders (HAND).
There are no known pharmacological therapeutics for the treatment of HAND.
Since neurodegeneration is irreversible, an early intervention strategy is key.
Dysregulation of dopaminergic neurotransmission has been implicated in
the persistence of HIV infection as well as the development of HAND (Nath et al.
2000; Purohit et al. 2011; Gaskill et al. 2017; Zhu et al. 2018). Clinical evidence
and animal studies have found dopaminergic neuron damage and disruptions in
DA metabolism in HIV-positive patients (Koutsilieri et al. 2002b; Silvers et al.
2006; Scheller et al. 2010; Horn et al. 2013; Meulendyke et al. 2014). The
dopamine transporter (DAT), the main regulator of DA homeostasis in the brain
via dopamine (DA) reuptake, is implicated in HIV infection as well. For instance,
clinical imaging studies reveal decreased levels of DAT in the brains of HIVpositive patients with dementia (Wang et al. 2004). Drugs of abuse such as
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cocaine, which inhibit DAT uptake and cause extracellular DA overflow, have
been

found

to

exacerbate

viral

replication

and

accelerate

HAND

neuropathogenesis (Peterson et al. 1990; Bagasra and Pomerantz 1993; Roth et
al. 2002; Steele et al. 2003; Dahal et al. 2015). In HIV-positive patients with a
history of cocaine abuse, DAT availability in the brain is further decreased
compared to patients with HIV-associated dementia, which correlated with
diminished

performance

in

neurocognitive

tests

(Chang

et

al.

2008).

Consequently, drug-induced increases in DA levels were found to promote HIV
viral replication and infection of macrophages and lymphocytes (Scheller et al.
2000; Gaskill et al. 2009, 2013). Furthermore, as infected cells continue to
accumulate in the brain’s viral reservoirs, neurotoxic viral proteins are released.
These viral proteins have been associated with the widespread neuropathology
in the brain as well as the development of HAND (Nath and Geiger 1998).
Among the viral proteins, Tat (trans-activator of transcription), has been found to
play a critical role in HIV-1 infection, viral replication, and the development of
neurocognitive deficits that lead to HAND (Mocchetti et al. 2012; Gaskill et al.
2017; Zhu et al. 2018).
Tat directly inhibits DAT through an allosteric mechanism, where it does
not directly compete with the transporter’s central substrate binding site (Zhu et
al. 2011; Midde et al. 2013; Yuan et al. 2015; Sun et al. 2017). DAT inhibition
leads to increased synaptic DA levels and continued Tat release, thereby
exacerbating viral infection and disruptions in dopaminergic signaling (Nath and
Geiger 1998; Purohit et al. 2011). Allosteric modulation is a novel approach to
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disrupt Tat-DAT binding by developing compounds to attenuate Tat binding to
DAT with minimal influence on basal DA transport. A novel series of quinazoline
structure-based compounds (the SRI compounds) have been developed, which
function as allosteric modulators of monoamine transporters and act as partial
antagonists of DA uptake without the full inhibitory profile that is typical of classic
competitors of DAT (Pariser et al. 2008; Rothman et al. 2015). It has been
recently found that these SRI compounds attenuate the inhibitory effects of Tat
as well as cocaine on DA uptake and binding (Zhu et al. 2011; Sun et al. 2017).
The computational model of the Tat-hDAT complex reveals that SRI-30827
interferes with the interaction of Y470 and Y88 with the EL6 region of hDAT,
which most likely interferes with Tat binding on hDAT via an allosteric
mechanism (Sun et al. 2017). It is therefore of great clinical and scientific interest
to utilize pharmacological probes that could block Tat binding to hDAT, especially
in HIV-positive patients who are concurrent abusers of cocaine.
In this study, novel allosteric DAT modulators were screened using a
heterologous cell line expressing wild-type human DAT (WT hDAT). After
selecting the most potent compounds, allosteric properties and ability to
attenuate the inhibitory effects of recombinant Tat1-86 (rTat1-86) protein in vitro was
characterized. Finally, it was determined whether the SRI compound would
alleviate Tat-potentiated cocaine rewarding effects in an inducible Tat transgenic
mouse model (iTat-tg). These proof-of-concept studies utilizing SRI compounds
as pharmacological probes will aid in characterizing the allosteric sites of DAT,
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paving the way for new therapeutic avenues for treating both cocaine addiction
and cocaine-potentiated HAND in HIV-positive individuals.
4.2 METHODS
4.2.1 Materials
Rat pheochromocytoma (PC12) cells and CHO cells were obtained from
ATCC (Manassas, VA). 3,4-[7-3H]DA (28 Ci/mmol) and [N-methyl-3H]WIN 35,428
(82.62 Ci/mmol) were purchased from Perkin Elmer (Boston, MA). The novel
DAT allosteric modulators (SRI compounds), were synthesized at Southern
Research Institute (Birmingham, AL). Cocaine hydrochloride and other fine
chemicals/reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwise
noted.
4.2.2 Molecular modeling
Molecular Docking techniques were used to identify the binding poses of
the hDAT homology model and SRI-32743 using Autodock Vina (Trott and Olson
2010). The homology model for hDAT was constructed using methods described
previously (Yuan et al. 2015). The 3D geometrical structure of each SRI
compound was built with GaussView 6 (Dennington et al. 2016). This 3D
structure, of each SRI compound was then used to generate a conformational
ensemble of 20 different compounds with varying rotatable bonds, which were
generated using OMEGA from the OpenEye Scientific Software package
(Hawkins et al. 2010). The atomic charges for the SRI compound were
determined as restrained electrostatic potential (RESP) fitted charges based on
the first-principles electronic structure calculations at the B3LYP/6-31 G* level
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with geometry optimization by using the Gaussian09 program (Bayly et al. 1993;
Frisch et al. 2009). The ligand-binding site of the hDAT homology model was
discovered by selecting a search space that included the extracellular end of the
transmembrane domain of hDAT in close proximity to the Tat protein. The best
protein-ligand binding conformation for the SRI compound was selected
according to the best binding score given by AutoDock Vina. For each SRI
compound, the selected binding conformation was combined with the
constructed hDAT-Tat structure with tLeap module of the AMBER16 Software
package (Case et al. 2005). Then the SRI-hDAT-Tat complex were optimized
with 4,000 steps of the deepest decent energy-minimization and 4,000 steps of
the conjugate gradient energy-minimization by using the Sander module of the
AMBER 16 package. This series of optimized minimization steps were carried
out by applying a harmonic constraint only on the protein and gradually reducing
the force constant from 300, 200, 100, 75, 50, and 25 kcal/mol/Å (Yuan et al.
2015). A final minimization step was carried out without applying any harmonic
constraint. Docking

models and

figures were

generated

using

Pymol

(Schrödinger 2015).
4.2.3 Construction of plasmids
Synthetic cDNA encoding the WT hDAT sequence (NCBI, cDNA clone
MGC: 164608 IMAGE: 40146999) subcloned into pcDNA3.1+ (provided by Dr.
Haley E Melikian, University of Massachusetts) was used to propagate plasmid
DNA. Plasmid DNA were propagated and purified using the Qiagen Hi-speed
maxi prep plasmid DNA isolation kit (Qiagen, Valencia, CA, USA).
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4.2.4 Cell culture
PC12 cells (CRL-1721, ATCC, Manassas, VA) were maintained at 37°C
(5% CO2) with RPMI-1640 medium (ATCC, Manassas, VA) supplemented with
horse serum (10%), fetal bovine serum (5%), and penicillin-streptomycin (100
U/ml). Chinese hamster ovary cells (CHO cells, ATCC, CRL-61) were maintained
in F12 medium with 10% fetal bovine serum and antibiotics (100 U/mL penicillin
and 100 µg/mL streptomycin). For transfection, cells were seeded into poly-Dlysine-coated 24 well plates at a density of 1×10 5 cells/well. After 24h, cells were
transfected with WT or mutant DAT plasmids using Lipofectamine 2000 (Life
Tech, Carlsbad, CA) based on the manufacturer’s instruction. Cells were used for
the experiments after 24 h of transfection.
4.2.5 [3H]DA uptake assay
To determine IC50 values of the SRI compounds or cocaine via [3H] DA
uptake, assays in PC12 cells transfected with WT hDAT was carried out
according to our previous studies (Quizon et al. 2016; Sun et al. 2017). Briefly,
assays were performed in duplicate in a final volume of 250 µl. Cells were
washed twice with Krebs-Ringer-HEPES (KRH) buffer and incubated with a
range of SRI concentrations (0.1 nM to 100 µM), cocaine concentrations (1nM1mM) or a fixed concentration of SRI-32743 (50 nM) or indatraline (10 nM) at
room temperature for 10 min. Next, cells were incubated for 8 min with a fixed
concentration of mixed [3H]DA (0.05 µM, 250,000 DPM per well). In parallel, the
non-specific [3H]DA uptake was determined in the presence of nomifensine (10
µM). Cells were lysed in 1% SDS for an hour and lysates were transferred into
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scintillation vials containing cocktail. After overnight incubation, samples were
read on a liquid scintillation counter (model Tri-Carb 2900TR; PerkinElmer Life
and Analytical Sciences, Waltham, MA). The IC50 values were determined using
Prism 8.0 (GraphPad Software Inc., San Diego, CA).
To determine the effects of SRI compounds on Tat-induced inhibition of
DA uptake, [3H]DA uptake assays were performed on PC12 cells transiently
expressing WT hDAT, according to our previously reported methods (Quizon et
al. 2016). In brief, cells were harvested and resuspended in 1X KRH buffer and
incubated for 20 min at room temperature with or without 140 nM of recombinant
Tat1-86 (ImmunoDX, Woburn, MA). The samples were then incubated with 0.05
µM [3H]DA for 8 min then filtered through Whatman GF/B glass filters (presoaked
with 1XKRH buffer containing 1 mM pyrocatechol for at least 3 h). Filters were
washed three times with 3 ml of ice-cold 1X KRH buffer containing pyrocatechol
using a Brandel cell harvester (model M-48; Brandel Inc., Gaithersburg, MD).
Radioactivity was determined as described above.
4.2.6 [3H]WIN35,428 binding assay
To determine the IC50 values of SRI compounds via [3H]WIN35,428
binding, competitive inhibition assays were carried out in duplicate in a final
volume of 250 µl using previously published methods (Sun et al. 2017). In brief,
PC12 cells transiently expressing WT hDAT were washed once with sucrosephosphate buffer and were then incubated with a range of concentrations of SRI
compounds (0.1 nM to 100 µM) in the presence of [3H]WIN 35,428 (5 nM) on ice
for 2 h. Non-specific binding was determined in the presence of 30 µM cocaine.
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After incubation, the intact cells in each well were washed twice with ice-cold
assay buffer, lysed by 1% SDS for 1 h and subjected to liquid scintillation
counting.
For the binding dissociation assay, experiments were conducted in a final
volume of 500 µl according to our previous publications (Zhu et al. 2011; Sun et
al. 2017). Intact CHO cells transiently expressing WT hDAT on 24-well poly-Dlysine coated plates were incubated with a fixed concentration of [3H]WIN 35,428
(5 nM) on ice for 2 h (steady state) followed by 2 washes of ice-cold assay buffer.
Non-specific [3H]WIN 35,428 binding was determined by addition of β-CFT
naphthalenedisulfonate monohydrate (10 µM). Buffer was added to all wells
before the initiation of the dissociation experiments and 50 µl of 10 µM cocaine,
and/or 50 nM SRI-32743 were added to assigned wells at indicated time points.
In condition 1 (10 µM cocaine only), 50 µl of cocaine was added to the 60 min
time point; 10 min later, cocaine was added to the 50 min time point, and so on.
At the 0 min time point, cocaine was added and immediately washed twice
alongside all the other wells. For condition 2 (10 µM cocaine + 50 nM SRI32743), 50 µl of cocaine and 50 µl SRI-32743 were added to the 60 min time
point; 10 min later, cocaine and SRI-32743 were added to the 50 min time point,
and so on. At the 0 min time point, only cocaine was added and immediately
washed twice alongside all the other wells. The cells were lysed with 1% SDS for
1 h and ran through a liquid scintillation counter the next day. For data analyses,
the 0 min timepoint where cocaine added but immediately washed was set as
100% to normalize samples at each time point in condition 1 and 2.
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4.2.7 Animals
Inducible Tat transgenic mice (iTat-tg) mice were generated at the
University of Florida where all animal studies were performed. The iTat mouse
line genetically expresses a tetracycline-on (TETON) system, which is integrated
into the regulator for the astrocyte-specific glial fibrillary acidic protein (GFAP)
promoter. The TETON system is coupled to the Tat1-86 gene, and with
doxycycline (Dox) administration, induces Tat1-86 expression in the mouse brain.
In the present study, 8 to 14-week-old male iTat mice were administered either
saline (control) or Dox for 14 days to determine whether the Tat-induced
potentiation of cocaine-CPP is reversed by allosteric modulator SRI-32743 (0.1,
1, or 10 mg/kg/day). C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME),
the background strain of iTat-tg mice, were used as non-transgenic control. Mice
were housed in 12 h light/dark cycle and had access to food and water ad
libitum. All animal procedures were approved by the Institutional Animal Care
and Use Committees at the University of Florida and conform to National
Research Council guidelines.
4.2.8 Cocaine Conditioned Place Preference (cocaine-CPP)
Mice were conditioned via a cocaine conditioned place preference
(cocaine-CPP) paradigm with the apparatus and automated measurement
system (San Diego Instruments, San Diego, CA) as previously described (Carey
et al. 2007; Paris et al. 2014). iTat-tg mice were tested for initial place preference
followed by 14-day administration of vehicle (0.9% saline) or Dox as described
above. On days 15 and 16, mice were administered (i.p.) vehicle (100% DMSO)
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or SRI-32743 (0.1, 1, 10 mg/kg/day) 60 min prior to cocaine or saline place
conditioning for 30 min. Preconditioning preference was determined by
measuring the amount of time individual mice spent in each chamber during a
30-min testing period. After administration of cocaine (10 mg/kg s.c.), mice were
immediately confined for 30 min in the initially non-preferred chamber.
Conditioning with vehicle (0.9% saline, s.c.) followed 4 h later in a similar
manner, but paired to the initially preferred chamber. This cocaine-saline
conditioning ‘cycle’ was repeated for two cycles, one cycle per day, for a total of
2 days. Mice were tested for preference 24 h after the completion of conditioning
by allowing the mice free access to the apparatus and measuring the time they
spent in each chamber over a 30-min testing period. On day 17, all mice were
given a final place preference test.
4.2.8 Data analysis and statistics
Descriptive statistics and graphical analyses were used as appropriate.
Results are presented as mean ± SEM, and n represents the number of
independent experiments for each experiment group. IC 50 values for cocaine
inhibition of [3H]DA uptake and [3H]WIN35,428 binding were calculated from
inhibition curves by nonlinear regression analysis with a one-site model of
variable slope. Emax for [3H]DA uptake and [3H]WIN35,428 binding were derived
from IC50 values and were calculated based on a previously reported equation
(Rothman et al. 2015). For the dissociation of [3H]WIN35,428 binding induced by
cocaine, the dissociation rate (K-1) was determined by the specific [3H]WIN35,428
binding through non-nonlinear regression analysis using a single component
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dissociation model. Both kinetic parameters (cocaine IC 50 and k-1) were
calculated by GraphPad Prism version 8.0 (GraphPad Software Inc., San Diego,
CA). For experiments involving comparisons between unpaired samples,
separate ANOVAs followed by appropriate post hoc tests (Bonferroni’s or
Student’s unpaired t test) were used. All statistical analyses were performed
using IBM SPSS Statistics version 24. Statistical significance was determined by
a minimum value of p<0.05.
4.3 RESULTS
4.3.1 SRI-32743 directly blocks Tat binding sites on hDAT
Docking studies were carried out with the insight that the SRI compounds
inhibit the binding of the Tat protein to the hDAT, leaving dopamine binding
unaffected (Sun et al. 2017). 3D models in Figure 4.1A show the Tat protein
(green) bound to the hDAT homology model (cyan) with bound DA (purple) and
the ligand binding site for the SRI compounds. DA is bound to the central cavity
while SRI-32743 (yellow) and Tat are allosterically bound to the extracellular
region of the transmembrane domain where the Tat protein interfaces with hDAT.
The identified ligand-binding site is one of three pockets where the Tat protein
forms close contact with the hDAT. Figure 4.1B shows a closer view of the
ligand-binding site with SRI-32743’s geometry complementing the groove of the
pocket. Figure 4.1C shows a global view of SRI-32743 and Tat binding to one of
the three known Tat binding pockets on the surface of hDAT. Figure 4.1D shows
a magnified surface view of Tat protein and SRI-32743 bound to the Tat binding
pocket on hDAT.
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4.3.2 SRI-32743 has the highest potency for inhibiting [3H]DA uptake among all
compounds screened
All 14 SRI compounds (Figure 4.2) were screened for the ability to inhibit
[3H]DA uptake and [3H]WIN35,428 binding in PC12 cells transiently expressing
WT hDAT. As shown in Table 4.1, SRI-32743 displays the highest potency in
inhibiting [3H]DA uptake (lC50: 9.86 ± 1.47 µM; Emax: 68.4 ± 8.56%) and an Emax
value below 70%, indicative of partial efficacy (Rothman et al. 2015). On the
other hand, SRI-35280-2 (lC50: 678.00 ± 72.79 µM; Emax: 83.6 ± 8.46%) and SRI36997 (lC50: 348.37 ± 54.56 µM; Emax: 83.2 ± 8.40%) have elevated lC50 and Emax
values compared to other compounds. For [3H]WIN35,428 binding, SRI-32743
(168.49 ± 63.94 µM) has the least potency for binding to the DA binding site
compared to other SRI compounds. Because SRI-32743 is a chiral drug, the
individual IC50 values of its R- and S- enantiomers for [3H]DA uptake and
[3H]WIN35,428 binding to hDAT were screened. For [3H]DA uptake, R-SRI-32743
(lC50: 16.02 ± 2.0 µM, t(7) = 2.37, p<0.05; Emax: 76.4 ± 9.09%) displayed an IC50
value that was higher than that of the original racemate SRI-32743, while lC50
and Emax values of S-SRI-32743 (lC50: 7.01 ± 2.0 µM; Emax: 70.7 ± 9.99%) remain
unchanged. On the other hand, [3H]WIN35,428 binding shows that R-SRI-32743
(lC50: 10.76 ± 1.7 µM, t(7) = 2.81, p<0.05; Emax: 54.3 ± 8.69%) and S-SRI-32743
(lC50: 4.69 ± 1.5 µM, t(7) = 2.92, p<0.05; Emax: 47.1 ± 8.97%) displayed lC50 and
Emax values that are significantly lower than that of SRI-32743.
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4.3.3 SRI-32743 increased the IC50 of cocaine
Like cocaine, indatraline is a potent direct competitor of [3H]DA uptake
(Pariser et al. 2008; Zhu et al. 2011; Sun et al. 2017). For these experiments,
indatraline was used as a positive control to assess whether SRI-32743 is a
direct competitor for DAT binding sites by determining its ability to alter cocaine’s
inhibitory effects on [3H]DA uptake. As reported in Table 4.2, compared to the
cocaine-only control (lC50: 196 ± 14 nM), the addition of 10 nM Indatraline
significantly increased cocaine’s IC50 by 172% (lC50: 533 ± 114 nM, t(6) = 2.97,
p<0.05). On the other hand, the addition of 50 nM SRI-32743 only resulted in a
45% increase in cocaine’s IC50 (lC50: 285 ± 30 nM, t(6) = 2.68, p<0.05). This
suggests that SRI-32743 is not a direct competitor for DA binding sites.
4.3.4 SRI-32743 slowed the dissociation rate of [3H]WIN35,428
To further confirm the allosteric properties of SRI-32743, dissociation
assay, which has been traditionally used to identify allosteric modulation of
ligands, was performed (Nandi et al. 2004; Pariser et al. 2008; Schmitt et al.
2013). It has been previously reported that SRI-20040, SRI-20041, and SRI30827 significantly slowed the [3H]WIN35,428 binding dissociation rate (k-1) in
WT hDAT (Zhu et al. 2011; Sun et al. 2017). As shown in Table 4.3, the
dissociation of [3H]WIN35,428 initiated by the addition of cocaine (10 µM)
proceeded in a monotonic manner which was well described by a single
component dissociation model (k-1 = 0.147 ± 0.022 min-1; Condition 1).

In

Condition 3 (10 µM Cocaine + 50 nM SRI-32743), the addition of 50 nM SRI32743 after cocaine significantly decreased cocaine-induced [3H]WIN35,428
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dissociation in WT hDAT (k-1 = 0.086 ± 0.014 min-1, t(7) = 2.419, p<0.05)
compared with cocaine alone. For Condition 2, 50 nM of SRI-32743 significantly
slowed down [3H]WIN35,428 binding dissociation (k-1 = 0.069 ± 0.010 min-1, t(6) =
3.196, p<0.02) compared to Condition 1. These results indicate that SRI-32743
does not compete with the DAT-selective inhibitor, [3H]WIN35,428 and
demonstrates properties consistent with known allosteric modulators (Rothman
et al. 2002; Zhu et al. 2011; Sun et al. 2017).
4.3.5 Both SRI-32743 and SRI-31596 attenuated the inhibitory effects of Tat on
DAT uptake
It has been previously demonstrated that Tat protein induces a 20-30%
decrease in specific [3H]DA uptake in cells expressing WT hDAT (Midde et al.
2013, 2015; Quizon et al. 2016; Sun et al. 2019). In the present study, SRI-32743
and SRI-31596 were used as pharmacological probes to determine whether Tat
protein inhibited DAT by acting on allosteric binding sites. The addition of 140 nM
recombinant Tat1-86 resulted in a 28% decrease in specific [3H]DA uptake in WT
hDAT (72.2 ± 4.47%, t(7) = 2.098, p<0.05). On the other hand, the addition of
either SRI-32743 alone or SRI-31596 alone did not alter specific [3H]DA uptake
compared to untreated control (SRI-32743 DPM: 2704 ± 453; SRI-31596 DPM:
2618 ± 480; Untreated Control DPM: 2714 ± 447). The inhibitory effects of 140
nM recombinant Tat1-86 in WT hDAT cells without SRI treatment was attenuated
by the addition of 50 nM SRI-32743 (120.9 ± 10.82%, t(8) = 4.16, p<0.01) and 50
nM SRI-31596 (145.4 ± 5.78%, t(8) = 10.01, p<0.001). These results show that
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SRI-32743 and SRI-31596 block Tat’s inhibitory effect on DAT on allosteric
binding sites.
4.3.6 Systemic in vivo administration of SRI-32743 alleviates Tat-potentiated
cocaine reward in iTat-tg mice
iTat-tg mice were tested for initial place preference followed by 14-day
administration of saline or Dox. On days 15 and 16, mice were administered (i.p.)
vehicle (100%DMSO) or SRI-32743 (0.1, 1, 10 mg/kg/day) 60 min prior to
cocaine or saline place conditioning for 30 min. On day 17, all mice were given a
final place preference test. As shown in Figure 4.4.A, SRI-32743 administration
dose-dependently alleviates potentiation of cocaine-CPP in iTat-tg mice treated
with Dox. Figure 4.4.B shows that a selected dose (1 mg/kg) of SRI-32743
attenuates potentiated cocaine-CPP in iTat-tg mice following 14-day Dox. Twoway ANOVA analysis reveal a significant main effect of place conditioning (F(1,274)
=10.43, p=0.0014) and treatment (F(1,274) =2.31, p=0.044), and significant
interaction of treatment and conditioning (F(5,274) =2.945, p=0.013). Whereas
treatment with Dox for 14 d significantly potentiated cocaine-CPP over salinetreated littermates (†; p=0.025), indicating that iTat potentiates cocaine-CPP,
treatment with SRI-32743 ameliorates the Tat-induced potentiation (‡; p=0.004).
4.4 DISCUSSION
As a follow-up to previous work (Sun et al. 2017), the current study tested
the feasibility of utilizing novel quinazoline-based allosteric modulators to
attenuate the effects of Tat inhibition on DAT function as well as Tat-potentiated
cocaine rewarding in the inducible HIV-1 Tat transgenic mouse model. There are
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six major findings in this study. First, preliminary results from the computational
model predicts that SRI-32743 blocks Tat at the known Tat binding sites on
hDAT. Second, among the SRI compounds screened, SRI-32743 has the highest
potency for inhibiting [3H]DA uptake while leaving [3H]WIN35,428 binding
unaffected as evidenced by its lowest binding potency. Third, both SRI-32743
and indatraline increased the cocaine IC 50 values of [3H]DA uptake. However,
SRI-32743 did this to a lesser degree compared to indatraline. This suggests that
unlike indatraline, SRI-32743 is not a direct competitor for DA binding sites on
DAT. Fourth, SRI-32743 alone or in combination with cocaine slowed the
dissociation rate of [3H]WIN35,428 compared to cocaine alone, demonstrating
that SRI-32743 does not compete with the putative DA or cocaine binding sites
on DAT. Fifth, both SRI-32743 and SRI-31596 attenuated the inhibitory effects of
Tat protein on DA uptake, thereby confirming computational predictions
regarding the SRI compounds’ ability to block Tat binding on DAT. Finally,
systemic pre-treatment with SRI-32743 ameliorated Tat-potentiated cocaine-CPP
in the iTat-tg mouse model. These results demonstrate that utilizing allosteric
modulatory compounds that disrupt Tat and DAT binding raise the exciting
possibility for potential therapeutics for the prevention of HAND especially in HIVinfected patients with concurrent cocaine abuse.
It has been previously demonstrated that Tat inhibits DA function by
binding to allosteric sites on DAT at specific recognition residues validated
through

a

combination

of

computational

modeling

predictions

and

pharmacological screening (Midde et al. 2013, 2015; Yuan et al. 2016b; Quizon
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et al. 2016; Sun et al. 2019). These residues do not lie on the central binding site
of hDAT, but may share the allosteric binding sites for both the SRI compounds
and Tat protein (Sun et al. 2017). Interestingly, preliminary results from the
computational modeling study appears to support this hypothesis. The three
binding pockets on hDAT that most favorably binds to Tat based on the outwardopen model of hDAT have been identified. The molecular dynamics simulations,
with the addition of SRI-32743 to the Tat-hDAT model, show that SRI-32743
favorably binds to one of the three Tat binding pockets on hDAT. Upon closer
inspection, these preliminary results show that SRI-32743 directly blocks Tat
protein from fully binding to its binding pocket on hDAT (Figure 4.1). This
prediction was validated experimentally in cells expressing WT hDAT. Both SRI32743 and SRI-31596 attenuated Tat-induced inhibition of DA uptake compared
to the non SRI-treated Tat-exposed control (Figure 4.3). Previous studies have
reported that SRI-30827 and SRI-20041 interact with key Tat recognition
residues Y470 and Y88 on hDAT (Midde et al. 2013, 2015; Sun et al. 2017).
Further studies are warranted in order to identify the specific residues on hDAT
as well as Tat that are involved in the ability of SRI-32743 as well as SRI-31596
for blocking Tat binding to hDAT.
Among the SRI compounds screened, SRI-32743 has the highest potency
for inhibiting [3H]DA uptake while leaving [3H]WIN35,428 binding unaffected as
evidenced by its lowest binding potency (Table 4.1). These results are interesting
because an ideal allosteric compound should have minimal or partial inhibitory
action on DAT with no effect on DA binding (Ananthan et al. 2002; Rothman et al.
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2002, 2015; Pariser et al. 2008). That is, the compound must be able to modulate
transporter function (i.e., [3H]DA uptake) without competing for the central
substrate binding site (i.e., as represented by [3H]WIN35,428 binding, which has
the highest binding selectivity for DAT). This condition would only be true if the
compound acts on sites that are distinct from the active binding site—i.e., in an
allosteric manner (Hasenhuetl et al. 2019). This finding agrees with previous
screenings conducted on rat synaptosomes where SRI-31142 was found to have
a 1000-fold weaker potency to block [3H[WIN35,428 binding compared to its
higher potency for inhibiting [3H]DA uptake (Rothman et al. 2015; Moerke et al.
2018). The current study also found that SRI-32743 and indatraline, a
competitive DAT inhibitor, increased the cocaine IC 50 values of [3H]DA uptake.
However, SRI-32743 increased cocaine IC50 values of [3H]DA uptake to a lower
degree compared to indatraline, which is consistent with previous findings with
SRI-20040 (Zhu et al. 2011). This suggests that unlike indatraline, SRI-32743 is
not a direct competitor for DA binding sites on DAT, effectively demonstrating its
allosteric characteristics.
Finally, as an initial test to determine the feasibility of utilizing allosteric
modulators like the SRI compounds to disrupt the potentiating effects of Tat on
cocaine-CPP, we utilized the iTat-tg mouse model. It has been previously found
that Tat protein potentiates cocaine-CPP in this mouse model due to Tat-induced
neurotoxicity and damage to dopaminergic areas of the brain (Paris et al. 2014).
This mouse model recapitulates many aspects of the neuropathological
phenotypes observed in HAND patients (Kim et al. 2003) and has been widely
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used to test the in vivo effects of Tat protein. In this study, SRI-32743 was
administered via i.p. injection, because of its excellent BBB penetration (data not
shown). Similar to the in vitro results shown in Figure 4.3, SRI-32743 blocked the
potentiating effects of Tat on cocaine-CPP in a dose-dependent manner (Figure
4.4). These results demonstrate the potential for using allosteric DAT modulators
like the SRI compounds to block the effects of Tat in vivo. Future studies should
determine whether the SRI compounds could ameliorate already established
cocaine-CPP in these mice. More studies regarding the ability of SRI compounds
to improve learning and memory in this mouse model would also be beneficial,
due to the cognitive deficits experienced by patients with HAND.
Overall, these results demonstrate that developing allosteric modulatory
molecules which attenuate cocaine and Tat binding to DAT offer the potential for
preventing HAND especially in HIV-infected patients who are concomitant
abusers of cocaine.
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Table 4.1. Summary of competitive inhibition studies on SRI compounds.

DAT Uptake
IC50
(µM)

DAT Uptake
Emax
%

DAT Binding
IC50 (µM)

DAT Binding
Emax %

SRI-29213

21.53 ± 3.50

69.4 ± 8.06

43.68 ± 14.62

69.4 ± 8.36

SRI-29786

21.34 ± 4.71

70.6 ± 8.45

35.44 ± 14.02

71.1 ± 7.64

SRI-30827

18.96 ± 4.81

74.2 ± 8.38

9.82 ± 1.70

74.8 ± 9.09

SRI-31142

24.68 ± 8.70

72.6 ± 8.19

7.15 ± 1.03

68.4 ± 9.35

SRI-31596

10.38 ± 0.59

70.5 ± 8.48

7.94 ± 1.30

68.4 ± 9.46

SRI-32743
SRI-352802
SRI-352822
SRI-36997

9.86 ± 1.47

68.4 ± 8.56

168.49 ± 63.94

71.4 ± 7.40

678.00 ± 72.79

83.6 ± 8.46

9.73 ± 2.26

73.3 ± 9.11

83.00 ± 24.96

78.7 ± 8.16

13.19 ± 0.76

74.1 ± 8.40

348.37 ± 54.56

83.2 ± 8.40

20.58 ± 1.00

71.3 ± 8.07

SRI-36998

12.09 ± 1.31

73.7 ± 9.04

5.32 ± 0.50

67.0 ± 9.85

SRI-39040

14.97 ± 0.47

75.8 ± 8.96

7.86 ± 1.04

69.7 ± 9.14

SRI-39041
SRI-32743
(R)
SRI-32743
(S)

12.61 ± 1.02

76.9 ± 8.95

6.41 ± 0.61

73.8 ± 9.91

16.02 ± 2.0

76.4 ± 9.09

10.76 ± 1.7

54.3 ± 8.69

7.01 ± 2.0

70.7 ± 9.99

4.69 ± 1.5

47.1 ± 8.97

Drug

Note: The Emax of cocaine is 100%
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Table 4.2. Effects of SRI-32743 on cocaine-induced inhibition of [3H]DA uptake in
WT hDAT.

IC50 (nM)
Condition 1
(Cocaine)

Condition 2
(Cocaine + Indatraline)

Condition 3
(Cocaine + SRI-32743)

196 ± 14

533 ± 114*

285 ± 30*

*P<0.05 compared to Condition 1. Data are presented as means ± SEM (n=4).
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Table 4.3. Effects of SRI-32743 on cocaine-mediated dissociation of [3H]WIN35,428
binding in WT hDAT.

Dissociation rate (k-1, min-1)
Condition 1
(Cocaine)

Condition 2
(SRI-32743)

Condition 3
(Cocaine + SRI-32743)

0.147 ± 0.022

0.069 ± 0.010*

0.086 ± 0.014*

*P<0.05 compared to Condition 1. Data are presented as means ± SEM (n=4).
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D

C
Tat

DAT

Figure 4.1 Preliminary molecular modeling of the Tat binding interface of the hDAT
homology model. DAT is shown in cyan, DA in purple, SRI-32743 in yellow, and Tat
protein in green. (A) The global view of the binding of Tat (green ribbon) and SRI-32743
(yellow stick) to hDAT. Notice that DA (purple sphere) is bound to the central cavity while
SRI-32743 and Tat are allosterically bound to the extracellular vestibule. (B) A closer
view of SRI-32743 bound to the external surface of hDAT highlighting how SRI-32743’s
geometry compliments the shape of the surface. (C) A global view of SRI-32743 and Tat
binding to one of the three known Tat binding pockets on the surface of hDAT. (D) A
magnified surface view of Tat protein and SRI-32743 competing for the Tat binding
pocket on hDAT.
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Figure 4.2 Novel series of quinazoline structure-based compounds screened. All of these compounds possess a common 4quinazolinamine core structure. SRI-29786 possess a monocyclic substituent and all others possess the fused bicyclic 6-(7methylimidazo(1,2-a)pyridyl system at the 2-position of the quinazoline ring. Compounds SRI-31142, SRI-31596, and SRI32743 are capable of crossing the BBB and are water-soluble.

Specific [3H]DA uptake
(% of control)

200

SRI alone (50 nM)
SRI + rTat1-86 (140 nM)

150

###

#

100

*
50

0

Control

SRI-32743

SRI-31596

Figure 4.3 SRI-32743 attenuates Tat-induced inhibition of DA uptake in WT hDAT.
Specific [3H]DA uptake in intact PC12 cells expressing WT hDAT was performed in the
presence or absence of Tat alone or SRI compounds, or Tat + SRI compounds. Data are
presented as a percent of untreated control per group, expressed as mean ± S.E.M.
(*p<0.01 compared to control with no Tat, # p<0.01 compared to WT hDAT within Tat
exposure group, n = 4-6).
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A

B

Figure 4.4 Systemic administration of SRI-32743 alleviates Tat-potentiated cocaine
reward in iTat-tg mice. (A) SRI-32743 administration dose-dependently alleviates
potentiation of cocaine-CPP in iTat-tg mice treated with Dox. (B) Selected dose (1
mg/kg) of SRI-32743 attenuates potentiated cocaine-CPP in iTat-tg mice following 14day Dox. (†; p=0.025; ‡; p=0.004). N=22-26 mice/bar as listed.

130

CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.1 CONCLUSIONS
The widespread availability of ART will increase the number of people
living with HIV worldwide. It has been estimated that by the year 2030, the
number of HIV-positive patients with HAND will grow by 5- to 10-fold (Cysique et
al. 2011). Mounting evidence from clinical and basic science research areas
have demonstrated the link between HIV viral protein Tat, dopaminergic
neurotransmission, and the dopamine transporter in the pathogenesis of HAND.
Tat protein blocks DAT leading to extracellular DA overflow, neurotoxicity, and
impaired dopaminergic neurotransmission that is further potentiated in the
presence of drugs of abuse such as cocaine. There are no targeted therapeutics
for the

treatment

of HAND, and

due

to

the

irreversible

nature

of

neurodegenerative diseases, a preventive early intervention strategy is critical.
Drug discovery efforts should focus on developing prophylactic neuroprotective
agents for HIV-positive patients to be taken with ART that would block Tat
without impeding normal DAT function.
This dissertation explored DAT as a potential target for disrupting Tat-DAT
binding through integrated computational modeling studies coupled with in vitro
pharmacological validation. Additional critical residues on hDAT for Tat were
identified, which includes H547 and D206. This work was the first to uncover
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H547A, an hDAT mutant that dramatically enhanced DAT function through
alterations in structure and sensitivity to posttranslational modifications like
phosphorylation and palmitoylation. The combination of DAT mutations were also
characterized, Y88F/D206L and Y88F/D206L/H547A, providing insights into
developing compounds that would block Tat binding on hDAT, presumably
through allosteric binding sites. An initial in vivo proof-of-concept study showed
the feasibility of utilizing allosteric modulator SRI-32743 to block Tat-potentiated
cocaine-CPP in iTat-tg mice.
The

findings

from

this

dissertation

will

contribute

to

improved

understanding of the dopamine transporter, which has been implicated not only
in the development of HAND, but in various diseases that stem from
dopaminergic dysregulation. Information from these studies will help contribute to
developing novel therapeutics for the treatment of such dopaminergic imbalances
as well as serve as the blueprint for creating an early intervention strategy for the
prevention of the development of HAND in HIV-positive patients.
5.2 FUTURE DIRECTIONS
The impact of HIV infection and the Tat protein on dopaminergic
dysregulation has been well studied (Purohit et al. 2011; Gaskill et al. 2017; Zhu
et al. 2018). HIV infection has been found to cause significant neuronal loss in
brain areas such as the PFC and the basal ganglia, which is reflected in
neurocognitive decline observed in patients with HAND (Küper et al. 2011). The
PFC, via both DA and norepinephrine (NE), is involved in complex cognitive
processing and organization of higher-order thinking and goal-directed behaviors
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(Fuster 1997). Elevated levels of NE during the course of HIV infection has also
been found to increase viral replication and disease progression (Cole et al.
1998; Ironson et al. 2008; Dever et al. 2016). Due to its high sequence homology
to DAT (80%) (Andersen et al. 2015), NET actively participates in the reuptake of
both NE and DA (Morón et al. 2002). The similarities between DAT and NET
necessitate further studies looking into the interaction between Tat protein and
NET to determine additional therapeutic targets for preventing HAND in HIVinfected individuals.
The work presented in this dissertation has laid the foundations for
characterizing the Tat-DAT binding complex. However, these studies were
carried out in vitro, which may not accurately reflect what occurs in vivo. The
iTat-tg mouse is a valid model that is widely used to study the biological effects of
Tat protein in vivo (Kim et al. 2003). Compared to cell-based studies that rely on
a fixed concentration of recombinant Tat1-86, the iTat-tg mouse endogenously
expresses Tat protein after induction with doxycycline. Common problems with
recombinant Tat1-86 such as instability, oxidation, and degradation (Gaskill et al.
2017) are avoided when the protein is endogenously expressed in a closed
biological system such as a transgenic mouse.
Further in vitro characterization studies of the Tat-DAT and Tat-NET
binding pocket can identify amino acid substitutions on DAT or NET that block
the effects of Tat while preserving normal transporter function. To determine
whether these findings hold true in vivo, knock-in mouse models bearing the
ideal DAT and/or NET mutations determined from in vitro studies should be
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generated and crossed with the iTat-tg mice and characterized pharmacologically
and behaviorally. The SRI compounds should continue to be tested on various
behavioral paradigms utilizing the iTat-tg mice. In this manner, Tat-DAT and TatNET disruption is tackled from both genetic and pharmacologic approaches,
paving the way for the ongoing development and further refinement of small
allosteric modulatory compounds that block the inhibitory effects of Tat while
preserving basal DAT and NET function.
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Table A.1. Summary of inhibitory activities in [3H]WIN 38,428 binding in WT-hDAT
and mutated hDAT

IC50 (nM)

DA

Cocaine

GBR12909

WT hDAT

1350 ± 382

308 ± 55

770 ± 193

H547A-hDAT

2416 ± 652

156 ± 36*

528 ± 120

* p<0.05 compared with WT hDAT (unpaired Student’s t test)
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1st antibody: 1:2000 (Rabbit anti-b-tubulin, Santa Cruz, H-253, SC-9014)
2nd antibody: 1:8000 (anti-rabbit-HRP 111-035-144, Jackson)
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Figure A.1 Supplementary data for Chapter 2.
Top left. Surface (biotinylated) and intracellular DAT expression. Samples were loaded
onto the gel and run under same experimental condition. Lanes indicate biotinylated
protein (b, d, f, h) and intracellular protein (a, c, e, g). Lanes d and f were cropped and
represented as surface DAT immunoblots for WT hDAT and H547A mutant,
respectively, in Fig 2B (top panel).
Lower left. Total DAT expression. Samples were duplicated and loaded onto the gel
and run under same experimental condition for WT hDAT (a, b), H547A (c, d), H547P (e,
f), and D206L (g, f, unpublished data). Lanes b and d were cropped and represented as
total DAT immunoblots for WT hDAT and H547A mutant, respectively, in Figure 2B (top
panel).
Blots on right. The same blots shown in left were reprobed with β-tubulin antibody,
which indicate an equal sample protein was loaded onto each lane.
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Figure B.1. Representative immunoblots of total and biotinylated WT hDAT (a, b)
and D381L (c, d).
Top-left: Total DAT expression in PC12 cells expressing WT hDAT or mutant. The total
fraction was loaded in duplicate onto the gel under the same experimental conditions.
Lanes a and c were cropped to represent Total DAT for WT and D381L, respectively, in
Figure 3C.
Bottom-left: Biotinylated (surface) and intracellular DAT expression in PC12 cells
expressing WT hDAT or mutant. The biotinylated and intracellular fractions were loaded
in duplicate onto the gel under the same experimental conditions. Lanes a and c were
cropped to represent Biotinylated DAT for WT and D381L, respectively, in Figure 3C.
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Blots on right: β-tubulin antibody was used to re-probe the corresponding blots on the
left in order to show that equal amounts of protein were loaded on each sample lane.
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Figure B.2. Representative immunoblots of total and biotinylated WT hDAT and D206L.
Top-left: Total DAT expression in PC12 cells expressing WT hDAT or mutant. The total
fraction was loaded in duplicate onto the gel under the same experimental conditions.
Lanes a and g were cropped to represent Total DAT for WT and D206L, respectively, in
Figure 3C.
Bottom-left: Biotinylated (surface) and intracellular DAT expression in PC12 cells
expressing WT hDAT or mutant. The biotinylated and intracellular fractions were loaded
in duplicate onto the gel under the same experimental conditions. Lanes a and g were
cropped to represent Biotinylated DAT for WT and D206L, respectively, in Figure 3C.
Blots on right: β-tubulin antibody was used to re-probe the corresponding blots on the
left in order to show that equal amounts of protein were loaded on each sample lane.
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Figure B.3. Representative immunoblots of total and biotinylated WT hDAT,
D206L/H547A, and Y88/D206L/H547A.
Top-left: Total DAT expression in PC12 cells expressing WT hDAT or mutant. The total
fraction was loaded in duplicate onto the gel under the same experimental conditions.
Lanes d, e, and f were cropped to represent Total DAT for WT, D206L/H547A, and
Y88F/D206L/H547A, respectively, in Figure 3C.
Bottom-left: Biotinylated (surface) and intracellular DAT expression in PC12 cells
expressing WT hDAT or mutant. The biotinylated and intracellular fractions were loaded
in duplicate onto the gel under the same experimental conditions. The WT,
D206L/H547A, and Y88F/D206L/H547A lanes were cropped to represent Biotinylated
DAT in Figure 3C.
Blots on right: β-tubulin antibody was used to re-probe the corresponding blots on the
left in order to show that equal amounts of protein were loaded on each sample lane.
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